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Abstract 
 
Hemogenic endothelium is a highly specialized population of vascular endothelial cells 
that produces hematopoietic stem cells (HSCs) during embryonic development. This 
process, referred to as the endothelial-to-hematopoietic transition (EHT), is critical to 
establish a functional hematopoietic system that persists throughout adulthood. The 
underlying genetic and cell signaling mechanisms that regulate human EHT remain poorly 
defined. Human pluripotent stem cells, including embryonic stem cells (hESCs) and 
induced pluripotent stem cells (hiPSCs) provide a well-defined cellular platform that can 
be used to study these mechanisms. In this work, functional human hemogenic endothelium 
was identified and isolated from the earliest hemato-endothelial cells differentiated from 
hESCs. Analysis of hemogenic endothelial cells at a single-cell resolution found hESC-
derived hemogenic endothelium was transcriptionally distinct from vascular endothelial 
cells lacking hematopoietic potential. Novel genetic markers distinguishing human 
hemogenic endothelium are also presented. Contributions from the aryl hydrocarbon 
receptor (AHR), an important cell signaling molecule in HSC biology, were also assessed 
at the level of human EHT. Small molecule inhibition and gene deletion of AHR 
significantly improved functional hematopoietic stem and progenitor cell development 
from hESCs. Importantly, a novel role for AHR in the development of hESC-derived innate 
lymphoid cells is also presented. Collectively, this dissertation identifies and describes key 
transcriptional and signaling mechanisms that support human EHT. This information will 
be useful to optimize the development of HSCs and other hematopoietic lineages that are 
suitable for future clinical application. 
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CHAPTER 1 
 
Background and Significance:  
 
Human hematopoietic development and hemato-endothelial differentiation from 
human pluripotent stem cells 
  2 
Overview of hematopoiesis and the birth of hematopoietic stem cells 
Hematopoiesis (αίµα: blood; ποiέω: to make) is a multi-factorial process that 
consists of temporally and spatially ordered phases over the course of human development. 
The first phase, termed the “primitive wave,” occurs exclusively within the extraembryonic 
yolk sac and is the only site of hematopoietic development between days 21-28 of human 
gestation1–3. Primitive hematopoiesis begins with the differentiation of mesodermal cells 
into progenitor cells that are bi-potent for hematopoietic and/or endothelial fates4. These 
primitive cells are referred to as hemangioblasts. When hemangioblasts differentiate, they 
form luminal outpouches into the exocoelomic cavity classified as blood islands2. The 
blood islands house the earliest hematopoietic cells prior to the development of the 
embryological vasculature network. 
Primitive hematopoiesis is largely dominated by the development of a transient 
population of immature erythroid cells enriched for the expression of embryonic globin 
genes, such as ε- and γ-globin3. In the mouse, these cells are termed primitive erythroid 
colony-forming cells (EryP-CFC) due to their ability to form colonies of large nucleated 
erythroid cells in semi-solid media culture. Importantly, EryP-CFCs quickly expand within 
the conceptus between embryological day (E) 7.25-8.25, but cease to exist after E9.0. 
These findings led to the consensus that primitive hematopoiesis is a transient wave of 
hematopoietic development and simply functions to generate oxygen-carrying erythroid 
cells to meet the high metabolic demands of embryogenesis4. Furthermore, while there is 
an abundance of EryP-CFC within the blood islands, significant numbers of 
megakaryocytic (Meg-CFC) and macrophage (Mac-CFC) colony-forming cells of 
  3 
undefined function have also been identified2. This led to the idea that a short-lived, 
multipotent hematopoietic stem cell with limited self-renewal capability (termed ST-HSC) 
exists within blood islands, but are not able to support the entire range of hematopoietic 
cell phenotypes found in the mature adult. 
Definitive hematopoiesis occurs as a second phase after the onset of primitive 
hematopoiesis. In mice, definitive hematopoiesis begins at E11.0, while in humans this 
process begins on Day 285. In both species, hematopoietic stem cells (HSCs) with 1) the 
ability to differentiate into every terminal hematopoietic cell phenotype, and 2) the ability 
to permanently engraft into an immunodeficient mouse model, is the hallmark of definitive 
hematopoiesis. HSCs arise directly from specialized vascular beds of endothelial cells 
referred to as hemogenic endothelium (HE). HE was first characterized from the ventral 
wall of the dorsal aorta-gonad-mesonephros (AGM) region6–8, but has secondarily been 
identified from the placental vasculature bed9–11, vitelline arteries12–14, and umbilical 
arteries13,15,16. In these sites, HE undergo a specialized process known as the endothelial-
to-hematopoietic transition (EHT). Live-cell in vivo imaging studies in both the mouse and 
zebrafish AGM using reporter genes to trace hematopoietic cells provided direct evidence 
of a phenotypic switch from adherent endothelium to non-adherent hematopoietic cells17–
19. These newly appearing cells were found to directly bud off from HE and enter the 
systemic circulation. On a molecular level, there are several gene and signaling networks 
that contribute to EHT (described below). Macroscopically, EHT is thought to, in part, be 
initiated by the onset of blood flow within the developing embryo. At the AGM, HE can 
sense fluid shear stress associated with blood flow, which in turn stimulates HSC 
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development20–23. This is induced by the upregulation of nitric oxide (NO) as a 
consequence of biomechanical stimulation, which has also been correlated to HSC 
specification21,23. Indeed, studies investigating definitive hematopoiesis using heartbeat-
less mouse and zebrafish models (Ncx1-/-) have demonstrated a dramatic reduction in 
hematopoietic clusters sprouting from the AGM24. Once initial HSCs emerge, they are 
carried within the circulation for further expansion and differentiation to the fetal liver 
(FL), thymus, spleen, and ultimately to the bone marrow where life-long hematopoiesis 
occurs25. 
 
Regulatory mechanisms of the endothelial-to-hematopoietic transition (EHT) from 
hemogenic endothelium 
The specification of functional HSCs from HE is a multifactorial process dependent 
on intrinsic gene expression and extracellular cues provided by the developing 
hematopoietic niche. The Notch signaling pathway has emerged as a major regulator of 
EHT and definitive hematopoiesis26–29. In brief, Notch signaling consists of four distinct 
Notch receptors (Notch 1-4), of which only Notch 1 and 4 contribute to definitive 
hematopoietic development30,31. These transmembrane receptors bind and respond to Delta 
(DLL1, DLL3, DLL4) or Jagged (JAG1, JAG2) ligand families presented on neighboring 
cells. This interaction triggers cleavage of the intracellular Notch domain (Nicd), which 
then translocates to the nucleus and heterodimerizes with recombining binding protein 
suppressor kappa (RBPjκ), that then functions as a transcription factor for many key 
hematopoietic genes32. AGM explants from Notch1-/- embryos were found to have reduced 
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hemato-endothelial potential as measured by colony-forming assays, but did not entirely 
abrogate HSC production30. This suggests that other complementary, Notch-independent 
pathways are also involved in EHT. 
One of the most important hematopoietic transcription factors regulated by Notch 
signaling is RUNX1. Overexpression of RUNX1 in both zebrafish and mouse Notch 
signaling mutants rescues HSC development within the AGM33,34. This finding supports 
that RUNX1 is, in part, directly regulated by Notch. RUNX1 has been referred to as the 
“master regulator” of definitive hematopoietic development35. RUNX1 is expressed in 
virtually all HSCs36–40, HE residing in the AGM41, and also some mesodermal progenitor 
cells42. In Runx1-/- embryos, primitive hematopoiesis develops normally, however, mid-
gestational lethality arises due to a complete loss of AGM and subsequent HSC 
formation41,43,44. The requirement for RUNX1 in EHT has been best demonstrated in 
studies using a Runx1 conditional knockout under the control of a tamoxifen-inducible VE-
cadherin (endothelial cell-specific) Cre recombinase37,45. In this system, Runx1 was not 
expressed in any blood cell where Cre recombinase was activated, confirming that RUNX1 
was required for definitive blood formation. Furthermore, Runx1 expression was redundant 
for hematopoietic stem and progenitor cell (HSPC) functionality once they initially formed 
from HE37. Similar function of RUNX1 in EHT has been further validated by Swiers, et 
al.46 at the single cell level. Using a GFP-reporter mouse of Runx1 gene expression, they 
demonstrated Runx1+ HSCs arise directly from Runx1+ HE. Moreover, Runx1- endothelial 
cells did not support a hemogenic program and failed to produce hematopoietic cells. 
  6 
Together, these studies confirm the activity of RUNX1 is crucial for the establishment of 
a definitive hematopoietic program in vertebrate systems. 
The RUNX1 gene consists of two promoters: a distal (P1) promoter and proximal 
(P2) promoter that are separated by 160 kb. An evolutionarily conserved intra-promoter 
+23 hematopoietic enhancer sequence is necessary for RUNX1 transcription47. The P1 
promoter transcribes the RUNX1c isoform and encodes a 19-amino acid longer protein at 
the N-terminus, currently of unknown function. The P2 promoter transcribes the shorter 
RUNX1a/b isoform. Interestingly, each promoter has differential activity dependent on the 
phase of hematopoiesis47–49. The P2 promoter is first active in yolk sac mesoderm and is 
required for embryonic viability by inducing primitive hematopoietic programs. The P1 
promoter becomes active later in development and is highly enriched within HSCs and 
definitive hematopoietic progenitor cells38,40. As such, acquisition of P1 promoter activity 
can be used as a “genetic switch” in tracking the exact moment when EHT begins. 
The +23 RUNX1 enhancer serves as a cis-regulatory element for several 
transcription factors with key roles in EHT36. Three prominent motifs include GATA, ETS, 
and E-BOX, which possess recognition sites for GATA2, FLI1 and SCL/TAL1, 
respectively50. GATA2 functions similarly to RUNX1 in that it is also, in part, driven by 
Notch1 activity. Haploinsufficiency of Gata2 significantly decreases the total number of 
HSCs derived from the AGM and complete Gata2 knockout results in lethality due to a 
lack of HSC production51–54. Recent evidence from the zebrafish model suggests that 
within HE, gata2b (a form of GATA2 that is restricted to HE exclusively in zebrafish) is 
required to initiate the expression of runx1 in a Notch-dependent fashion55. Fli1 functions 
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upstream of both Gata2 and Runx1, and is one of the earliest genes expressed in the 
specification of HE56. Fli1 expression is enriched within the AGM simultaneously as 
Runx1 and is also observed in newly developed hematopoietic progenitors57,58. Fli1-
deficient embryos generate almost identical phenotypes as Runx1-deficient and Gata2-
deficient embryos, thus highlighting its important role in vascular and hematopoietic 
specification59. SCL/TAL1 also functions upstream of RUNX1 activity, however its role 
in definitive hematopoiesis is less clear56. SCL/TAL1 appears to be important for both 
primitive and definitive hematopoietic development, as Scl/Tal1 knockouts fail to produce 
any hematopoietic cells, including primitive erythrocytes60–62. Furthermore, mesodermal 
progenitor cells lacking Scl/Tal1 expression failed in forming blast colonies in 
methylcellulose assays, further indicating its crucial role in the establishment of functional 
HE 63. 
Two families of homeobox proteins (Hox and Sox) have also been implicated in 
EHT. In particular, HOXA3 is an important negative regulator of mouse definitive 
hematopoiesis. Overexpression of HoxA3 is associated with repression of Runx1 and other 
hematopoietic-specific genes, while HoxA3 repression is associated with increased Runx1 
expression and retention of an endothelial cell phenotype64. HOXB4 is suggested to 
function as a molecular switch in conferring lymphoid potential to otherwise primitive 
hematopoietic cells developed from mouse embryonic stem cells65. However, it seems 
HOXB4 is redundant in human cells, as expansion and long-term engraftment of 
hematopoietic cells derived from HOXB4-overexpressed human embryonic stem cells 
(hESCs) was not achieved66. HOXA9 has been implicated in human EHT, but again, is not 
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sufficient on its own to confer long-term engraftment67. Dou et al.68 recently implicated 
medial HOXA genes to be key regulators of HSC maintenance, but these genes were 
silenced in hESC-derived hematopoietic cells. This suggests the HOXA locus may be a key 
regulator in developed AGM to produce engraftable hematopoietic cells. In human EHT, 
SOX17 has also recently been identified as a genetic marker of HE and that it is required 
for the development of the earliest hematopoietic progenitor cells in a Notch-dependent 
fashion69–72.   
Notch-independent signaling pathways have also been identified as important 
players in EHT. Wnt signaling is especially active in lateral plate mesoderm during 
embryogenesis and several key Wnt-associated molecules are overexpressed in the 
AGM73–76. Furthermore, addition of small molecules used to hyperactivate Wnt effector 
responses have increased the yield of HSPCs with lymphoid potential in zebrafish, mouse, 
and human models of hematopoiesis77–79. Bone morphogenic protein-4 (BMP4), a member 
of the TGF-β superfamily, has also been shown to support hemato-endothelial specification 
from the lateral plate mesoderm80. Addition of BMP4 to cell culture enhances 
hematopoietic activity, and does so by converging on both GATA2 and RUNX1 to promote 
a definitive hematopoietic program80–82. Taken together, EHT is a complex process that is 
dependent on many signaling and transcriptional modalities that function in a well-
concerted manner during embryogenesis to produce the earliest hematopoietic cells (Figure 
1-1). 
 
Modeling human hematopoiesis using human pluripotent stem cells 
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Our understanding of the earliest events of human hematopoiesis has mostly 
developed from studies using mouse models. While the mouse hematopoietic system is 
similar to that of humans, there are several major differences between species that 
necessitate study with human cells to appropriately understand human hematopoietic 
development. First, the balance of adult blood leukocytes is significantly different. Mouse 
blood is skewed towards lymphocytes (75-90% B-, T-, and NK cells; 10-25% neutrophils), 
while human blood is skewed towards neutrophils (50-70% neutrophils; 30-50% 
lymphocytes)83,84. Second, surface antigens specific to HSC phenotypes are different 
(Mouse: CD34-/loc-kithiCD38+Flt-3-; Human: CD34hic-kitloCD38-Flt-3+) as well as the 
chronicity between HSC divisions85,86. Third, IL-7 receptor-mediated signaling is required 
for mouse B-cell lymphopoiesis, but it is dispensable in humans83,87. Fourth, as previously 
mentioned, HOXB4 overexpression expands mouse HSCs, but not human HSCs, 
suggesting HSC self-renewal is different between species65,66,87.  Fifth, erythroid cell 
maturation differs in globin switching mechanisms3. Lastly, innate immune cell surface 
immunophenotype is highly variable between species, potentially lending to differences in 
function87,88. 
Human pluripotent stem cells, such as human embryonic stem cells (hESCs) and 
human induced pluripotent stem cells (hiPSCs), provide an excellent platform for studying 
the earliest events of human hematopoietic development and differentiation of HSPCs into 
terminal blood lineages. The first hematopoietic derivations from hESCs were 
demonstrated by Kaufman et al., in which hESCs co-cultured with murine bone marrow 
stroma or yolk sac endothelial cells produced CD34+ hematopoietic cells with myeloid, 
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erythroid, and megakaryocytic colony-forming potential89. Although this seminal study did 
not generate cells of lymphoid lineage, other groups have modified hESC conditions using 
various stromal cell co-culture and defined cytokine approaches to promote hemato-
lymphoid development. Vodyanik et al.90 and Choi et al.91 co-cultured hESCs with the 
OP9 mouse bone marrow stromal cell line in the absence of additional hematopoietic 
cytokines. This method generated HSPCs with multilineage potential, including B-
lymphocytes and natural killer (NK) cells. Timmermans et al.92 expanded on this method 
using a OP9 cell line genetically engineered to overexpress DLL1 (OP9-DL1) to generate 
CD3+ T-lymphocytes with functional T-cell receptors. To better recapitulate the AGM and 
developing hematopoietic niche, Gori et al.93 recently utilized engineered endothelial cell 
lines that overexpressed two Notch-related ligands, JAG1 and DLL4, to differentiate non-
human primate iPSCs into hematopoietic cells. Interestingly, these iPSCs generated 
massive quantities of CD34+CD45+ hematopoietic progenitor cells as compared to non-
endothelial cell culture. They also found longer engraftment time of CD34+ cells in 
secondary transplant recipients with multilineage potential, but they only assessed as far as 
12 weeks. These data highlight the importance of recapitulating the developing human 
hematopoietic niche for the production of multilineage HSPCs from hESCs/hiPSCs. 
Cytokines and small molecules have also been used to influence differentiation of 
definitive hematopoietic cells from human pluripotent stem cells. The addition of TGF-
β/Activin/Nodal inhibitors has been one successful strategy. Since TGF-β/Activin/Nodal 
signaling is crucial for primitive erythropoiesis94, inhibition of this pathway could skew 
hematopoietic development towards definitive lineages. Indeed, treatment of hESC 
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cultures with Activin/Nodal inhibitors minimized production of primitive progenitor cells 
and supported definitive hematopoietic development77,78. Wnt signaling has also been 
amplified using GSK-3 inhibitors (thus, increasing transcription of Wnt effector targets) to 
promote the development of hemato-lymphoid cells, suggesting enhanced definitive 
hematopoiesis lineage commitment79,95. New evidence using a combination of TGF-
β/Activin/Nodal and GSK-3 inhibition further improved hemato-lymphoid potential from 
hiPSCs as compared to either treatment alone96. 
While various stromal cell platforms and defined additives have been employed, no 
in vitro method alone to date has developed true HSCs that are multipotent and capable of 
life-long, permanent engraftment from hESCs/hiPSCs. However, there are two published 
studies that demonstrate hiPSCs can yield transplantable HSCs97,98. In each case, 
undifferentiated hiPSCs were injected into immunocompromised mice and allowed to form 
self-assembled teratomas. HSPCs and mature lymphoid cells could be isolated from 
dissected teratomas, with some HSPCs capable of multilineage reconstitution. 
Hematopoiesis was enhanced with the co-injection of OP9 cells intra-teratomally. While 
these HSPCs cannot be used for clinical purposes due to xenotransplantation and inefficient 
yield, these studies provide crucial evidence on a basic level that hESCs/hiPSCs possess 
the intrinsic capacity to differentiate into HSPCs ex utero. However, these studies also shed 
light on their dependency of a local and embryological-like microenvironment to fully 
mature into functional hematopoietic cells.  
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Innate lymphoid cell (ILC) development and differentiation from human pluripotent 
stem cells 
Innate lymphoid cells (ILCs) are a relatively newly defined grouping of lymphoid 
cells that contribute important factors to the innate immune response in blood and mucosal 
barriers99,100. In essence, ILC development, phenotype, and function in the innate immune 
response correlates to that of T-lymphocytes in the adaptive immune response101. Group 1 
ILCs are comprised of conventional natural killer (cNK) cells (analogous to CD8+ 
cytotoxic T-cells) and non-toxic ILCs (ILC1) that secrete TNF and IFNγ102,103. Group 2 
ILCs (ILC2) are analogous to CD4+ TH2 helper cells in that they secrete IL-4, IL-5, IL-9, 
and IL-13 to facilitate Type 2 inflammatory responses99. Human Group 3 ILCs (ILC3) are 
a heterogeneous population that can be subdivided into two groups based upon expression 
of natural cytotoxicity receptor (NCR; NKp44 and NKp46). NCR+ ILC3 can express and 
secrete IL-22104–106. Developmentally related to Group 3 ILCs are lymphoid tissue inducer 
(LTi) cells, which are required for secondary lymphoid organ development107. 
Confounding these classifications is an increasing body of evidence that suggest ILC 
subsets are plastic and may transform into other ILC phenotypes. As such, deconvoluting 
the heterogeneity of human ILCs remains an active area of research99,102,103,107. 
All lymphocytes stem from a common lymphoid progenitor (CLP) cell4. While B-
lymphocyte development in the bone marrow and T-lymphocyte development in the 
thymus have been well-characterized, human ILC development remains unclear. The first 
specification of ILCs is dependent on TOX and NFIL3 (also referred to as E4BP4) to 
produce a combined NK/ILC progenitor cell that lacks B- and T-lymphocyte potential108–
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110 . This cell, sometimes referred to as an α-lymphoid precursor (αLP) and interchangeable 
with the nomenclature “pre-NK cell”, uniformly expresses CD34, CD45RA, CD117 and 
α4β7 integrin, but lacks other ILC developmental markers such as CD56 and 
CD9499,102,111. αLPs are thought to then specify either into NK cell progenitors (termed 
“iNK cell”) or LTi/ILC progenitors in part by the activity of ID2 and GATA3. GATA3 gene 
ablation in HSCs prevents the development of ILCs (mainly ILC2), but does not affect NK 
cell development112–114. iNK cells at this stage begin to acquire NK cell-like functionality 
in producing IL-5, IL-13, and tumor-necrosis factor-related apoptosis inducing ligand 
(TRAIL)115. Next, iNK cells continue to develop into matured NK cells, first becoming a 
cytotoxic CD56bright NK cell that begins to express mature NK cell surface antigens 
(CD94/NKG2A, NKG2D, NKp46), and ultimately transitioning into a CD56dim NK cell 
with full cytotoxic potential116. EOMES, T-BET, and ID2 have all been identified as key 
transcription factors mediating iNK maturation117. On the other hand, murine studies show 
that ILC/LTi progenitors can differentiate into LTi cells based on expression of RORC or 
can commit to ILC lineages based on expression of PLZF99. From here, specification into 
ILC1, ILC2, and ILC3 cells is predominantly under transcription factor control. ILC1 
specification is dictated by T-BET, ILC2 by GATA3, and ILC3 by RORγt. The aryl 
hydrocarbon receptor (AHR) has also been shown to been indispensable for functional 
ILC3 differentiation118,119. 
The Kaufman lab has pioneered NK cell differentiation from human pluripotent 
stem cells. The initial report utilized a two-step culture method—first to differentiate 
CD34+CD45+ hematopoietic progenitor cells from hESCs on mouse stroma and then 
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defined conditions to support NK cell differentiation120. Here, cytokines that induced 
peripheral and umbilical cord blood CD34+ differentiation into NK cells (Flt3-L, SCF, IL-
3, IL-7, and IL-15) were used to generate CD56+CD45+ cells that co-expressed matured 
NK cell surface antigens, such as NKG2A, NKp44, NKp46, and KIR. These hESC-derived 
(and later hiPSC-derived) NK cells also possessed direct cytotoxic activity against 
leukemia, solid tumors, and HIV infected CD4+ T-cells120–124. It was later found that co-
culture using OP9-DL1 prevented differentiation towards T-lymphoid lineages and instead 
increased NK cell development125. Mature hESC- and hiPSC-derived NK cells once 
differentiated can also be expanded similar to peripheral blood-derived NK cells when 
cultured in the presence of IL-2 and stimulated with membrane bound IL-21 expressing 
antigen presenting cells126,127.  
 
The aryl hydrocarbon receptor (AHR) and its role in human hematopoiesis 
The AHR is a member of the Per/Arnt/Sim (PAS) family of environment-sensing, 
basic helix-loop-helix transcriptional regulators128–130. AHR is a cytoplasmic receptor that 
normally is stabilized by co-chaperone protein HSP90, X-associated protein 2 (XAP2), and 
p23131–133. Following ligand binding to AHR, the HSP90:XAP2:p23 complex is removed 
and becomes stabilized by ARNT/HIF1β (aryl hydrocarbon nuclear translocator/hypoxia-
inducible factor 1β), forming a functional heterodimer. This heterodimer subsequently 
binds to the 5’-GCGTG-3’ consensus within xenobiotic responses element (XRE) that is 
located immediately upstream of several AHR target genes, such as CYP1A1, CYP1B1, 
AHRR, IL-17, and IL-22 (Figure 1-2). AHR homology is evolutionarily conserved across 
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diverse species and has historically been studied for its role as a mediator of cellular 
toxicity in response to environmental pollutants134.  
Recent studies have shown AHR is expressed in many tissues during embryonic 
development and its signaling can have broad effects on genes that influence development, 
proliferation, differentiation, and the innate immune response135–137. Endogenous AHR-
mediated signaling has been shown to play a potential role in developmental 
hematopoiesis. Genetic profiling studies and computational analyses from mouse models 
reveal Ahr is expressed in hematopoietic stem cells (HSCs)130,138. Ahr expression is highest 
in immature hematopoietic cells (including immature B-cells, T-cells, and bone-marrow 
derived Sca+ HSCs) relative to terminally differentiated phagocytes, dendritic cells, 
erythroid cells, T-cells, and megakaryocytes138. AHR activation is also required for the 
development of Th17 cells, regulatory T-cells, and ILC3129,137,139,140. A high-throughput 
screen to identify compounds that promote expansion of CD34+ umbilical cord blood ex 
vivo discovered that StemReginin-1 (SR-1), a potent AHR antagonist, could increase the 
number of engraftable CD34+ cells at least 17-fold and are suitable for transplant141. 
Indeed, Wagner et al.142 recently transplanted expanded umbilical cord blood-derived 
CD34+ cells treated with SR-1 in a Phase I/II clinical trial. SR-1 treated CD34+ cells 
robustly expanded over 300-fold and conferred faster time to engraftment of neutrophils 
and platelets relative to patients treated with manipulated units. These breakthroughs 
demonstrate that AHR may also be a crucial mediator of HSC growth and differentiation. 
Indeed, Ahr-/- mice present with splenomegaly, altered numbers of erythrocytes and 
leukocytes, and a 2-fold enhancement in HSC-enriched Lin-Sca+c-Kit+ cells in the bone 
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marrow compartment143. Furthermore, Ahr-/- mice are susceptible to lymphoma and other 
hematological malignancies144.  Collectively, these data suggest that AHR may also serve 
as a critical regulator of definitive hematopoiesis. AHR expression is required to maintain 
HSC quiescence and hematopoietic progenitor cell differentiation, while AHR repression 
is necessary to promote expansion and maturation of HSCs and terminal hematopoietic 
cells. It remains unknown what, if any, specific role AHR plays earlier in the process of 
early human hematopoietic lineage commitment. It is also unclear whether AHR signaling 
is important for the specification of mesoderm-derived cells into primitive and/or definitive 
hematopoietic cells via EHT mechanisms. 
 
Thesis Statement 
The experiments described in this dissertation contribute novel information to our 
understanding of human endothelial and hematopoietic development. Previous 
knowledge of these processes has largely been derived from studies that are dependent on 
non-human animal models, which do not perfectly correlate with human biology. By 
using human pluripotent stem cells to model the earliest events of hematopoiesis, we can 
identify unique biological features of the endothelial-to-hematopoietic transition (EHT) 
and the maturation of adult blood cells that are specific to human development. 
Furthermore, these data can be extrapolated to optimize the production of HSPCs that 
may be suitable for treating patients with hematological and immunological pathologies. 
In Chapter 2, we first establish an approach to define functional human 
hemogenic endothelial cells using a combination of endothelial cell surface antigens and 
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the expression of RUNX1c, a key EHT gene. With this schema, we analyzed the 
transcriptional signatures of individual cells from three distinct populations 
simultaneously derived from hESCs: hemogenic endothelial cells, vascular endothelial 
cells that lack hematopoietic potential, and early hematopoietic progenitor cells. Here, we 
determined human hemogenic endothelial cells have a similar transcriptional signature as 
the earliest hematopoietic progenitor cells, but both populations are distinct from vascular 
endothelial cells lacking hematopoietic potential. We also present novel genetic 
candidates that distinguish hemogenic endothelium from non-hemogenic endothelium. 
These genes possessed high predictive value in conferring hemogenic endothelial and 
hematopoietic phenotype. As such, these genes serve as excellent candidates for future 
gain-or-loss of function studies to promote a uniform population of hemogenic 
endothelium from human pluripotent stem cells. 
In Chapter 3, we expand on the current role of AHR in the normal physiology of 
human hematopoietic development. Here, we demonstrate AHR modulates hematopoietic 
potential at the level of EHT. AHR antagonism using small molecules and AHR gene 
deletion both enhanced early hemato-endothelial differentiation from hESCs. This is the 
first evidence that suggests AHR is functional prior to the development of a CD34+ 
HSPC. We further utilize AHR inhibition as a method to enhance hemato-lymphoid 
differentiation from hESCs, specifically ILCs. We specifically demonstrate ILC3 
dependency on AHR activity and, as such, is the first evidence of human ILC3 
differentiation from human pluripotent stem cells. This method can serve as a platform in 
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future studies to better understand the developmental biology and function of human 
ILCs and other hemato-lymphoid cell subsets. 
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Figure 1-1. Key cell signaling and transcriptional regulators of human hemogenic 
endothelial cells. RUNX1c forms a transcriptional complex between GATA2, FLI1, and 
SCL/TAL to regulate the endothelial-to-hematopoietic transition (EHT). Upstream 
activation of Notch, VEGF, BMP4, and Wnt signaling promote the activity of RUNX1c 
(green arrows), while the TGFβ/activin/nodal signaling pathway inhibits RUNX1c 
activity (red arrows). Some Hox/Sox transcription factors further contribute to the 
activity of RUNX1c-mediated EHT. 
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Figure 1-2. Canonical AHR signaling. AHR agonist ligands (green) are derived from 
dietary, microbial metabolism, human metabolism, or exogenous/environmental sources. 
AHR antagonists (red) are exogenously produced. SR-1 and TCDD (bold) possess the 
most potent activity in either class. Upon AHR activation, AHR disassociates from a 
cytoplasmic HSP90:XAP2:p23 co-chaperone complex and translocates into the nucleus. 
Here, AHR forms a heterodimer with ARNT and binds to xenogenic-response elements 
(XRE) to affect downstream gene transcription. AHR can be sequestered in the 
cytoplasm using AHR antagonists, thereby preventing effector gene target transcription. 
Adapted and modified from references 131,145,146. 
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CHAPTER 2 
 
Single cell resolution of human pluripotent stem cell derived hemato-endothelial cells 
reveals distinct transcriptional signatures of hemogenic endothelium 
  22 
ABSTRACT 
 
The endothelial-to-hematopoietic transition (EHT) mediated by hemogenic 
endothelium is an important stage in definitive hematopoietic development. Although EHT 
has been visualized both in vitro and in vivo, a thorough understanding of the genetic 
mechanisms underlying hemogenic endothelial cell fate remains poorly understood, 
especially in the humans. Using human pluripotent stem cells as a model for EHT, we 
hypothesized human hemogenic endothelium is phenotypically and transcriptionally 
distinct from other vascular endothelial cells and the earliest hematopoietic progenitor 
cells. We employed defined culture methods to differentiate hemogenic endothelial cells 
(HE, defined as CD31+CD144+CD41-CD43-CD45-CD73-RUNX1c+), vascular endothelial 
cells without hematopoietic potential (non-HE, defined as CD31+CD144+CD41-CD43-
CD45-CD73-RUNX1c-), and hematopoietic progenitor cells (HP, defined as 
CD34+CD43+RUNX1c+) from hESCs engineered with a RUNX1c-tdTomato reporter. 
Using these defined cell populations, we performed single-cell RNASeq on 55 HE, 47 non-
HE, and 35 HP cells. HE and HP were both highly enriched in genes implicated in known 
hemogenic endothelial transcriptional networks, such as CDH5, ERG, GATA2, and FLI. 
Using t-distributed stochastic neighbor embedding (t-SNE) analysis, we found 
transcriptional overlap between individual HE and HP cells; however, these populations 
were distinct from two, separate groupings of non-HE. Further analysis revealed novel 
biomarkers for human HE/HP cells, such as TIMP3, ESAM, RHOJ, and DLL4. One subset 
of non-HE cells was enriched for several extracellular matrix genes and suggestive of a 
previously reported endothelial-to-mesenchymal transition (EndMT). Taken together, we 
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demonstrate that hESC-derived HE and HP share a common developmental pathway, while 
non-HE are heterogeneous and transcriptionally distinct. Our findings provide a novel 
strategy to test new genetic targets and optimize the production of definitive hematopoietic 
cells from human pluripotent stem cells. 
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INTRODUCTION 
Hemogenic endothelium is a rare and highly specialized subset of vascular 
endothelial cell that functions as a precursor population to blood development17,18,28,147. In 
mammals, hematopoiesis occurs in two sequential phases in a defined temporo-spatial 
manner2,3,148. Hemogenic endothelium is associated with the definitive phase of 
embryological hematopoiesis, which is characterized by the life-long development of 
multipotent hematopoietic stem and progenitor cells (HSPCs)4,149. One of the hallmarks of 
definitive hematopoiesis is the endothelial-to-hematopoietic transition (EHT), a process 
where hemogenic endothelial cells phenotypically switch from a stationary endothelial cell 
state to a detached and free-moving HSPC. Although EHT has been visualized both in vitro 
and in vivo at specific anatomical landmarks via lineage tracing studies18,150,151, the 
regulation of this fate change at both a cellular and molecular level remains unclear. 
Confounding this knowledge further is an absence of unique cell surface markers allowing 
phenotypic identification and isolation of hemogenic endothelium from other 
developmentally related cell types46,152. Furthermore, specific hemogenic endothelial cell 
genetic identifiers from humans have yet to be adequately defined.  
One candidate identifier of human hemogenic endothelium is RUNX1c, an isoform 
of the RUNX1 gene. Expression of the +24 intronic enhancer, which drives RUNX1c 
expression via the P1 promoter, has been shown to be restricted to a subset of endothelial 
cells where de novo generation of HSPCs occurs in both zebrafish and mouse models36,46. 
RUNX1c expression has also been correlated exclusively to human definitive 
hematopoietic cells, including CD34+ umbilical cord blood and hematopoietic stem cells37–
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40,153,154. Our lab, and others, have previously described human EHT using a human 
RUNX1c pluripotent stem cell reporter system77,95. As such, RUNX1c can serve as a genetic 
basis for selecting human hemogenic endothelial cells from other developing endothelial 
and hematopoietic cell populations. 
Human pluripotent stem cells, such as human embryonic stem cells (hESCs) and 
induced pluripotent stem cells (hiPSCs) serve as a useful platform to understand basic 
mechanisms underlying human EHT. We, and others, have previously shown 
differentiation of early hematopoietic progenitor cells from hESC-derived bi-potent 
endothelial cells capable of developing into cells of the erythroid155,156, myeloid89,157–159, 
and lymphoid lineages78,160,161. However, production of functional and long-term 
engraftable HSPCs from hESCs/hiPSCs in vitro has yet to be achieved. One hypothesis is 
that hESCs are biased toward primitive hematopoietic lineages, and fail to adequately 
generate hemogenic endothelial cells that produce definitive hematopoietic cells158,162–164. 
To assess this degree of heterogeneity from an hESC/hiPSCs system, single-cell RNA 
sequencing has emerged as an invaluable tool to discover novel and rare cellular subsets 
otherwise obscured in bulk RNASeq experiments165–168. 
In the present study, we utilized hESCs previously engineered to express a 
RUNX1c-tdTomato reporter construct77 to investigate the transcriptional signatures of 
human hemogenic endothelial cells (HE), vascular endothelial cells that lack hematopoietic 
potential (non-HE), and the earliest definitive hematopoietic progenitor cells (HP). We 
sequenced and analyzed 137 individual cells and performed comprehensive biostatistical 
analyses to reveal that endothelial cells derived from hESCs are heterogeneous in nature. 
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Human hemogenic endothelial cells and early hematopoietic progenitors shared similar 
gene expression signatures, suggesting a common developmental lineage. Intriguingly, 
vascular endothelial cells were found to be distinct from HE and HP, with a unique 
population of cells transformed into a mesenchymal/fibroblast-like cell phenotype. These 
studies now allow us to define novel genetic biomarkers to distinguish HE from non-HE 
and serve as a unique strategy to optimize definitive hematopoietic cell differentiation from 
human pluripotent stem cells.  
 
MATERIALS AND METHODS 
Human embryonic stem cell (hESC) culture 
hESC-RUNX1c-tdTomato reporter cells were previously engineered and validated 
in our lab77. In brief, a 1 kb fragment of the human RUNX1c P1 promoter and 250 bp 
conserved intronic region of the +24 enhancer were flanked by tdTomato. Upstream, a 
constitutively active GFP:zeo fusion protein permitted identification of cells differentiated 
from hESCs with stable reporter integration. hESC-RUNX1c-tdTomato were TrypLE 
adapted for single cell culture and maintained on irradiated mouse embryonic fibroblasts 
(MEF) in ES growth media consisting of Dulbecco’s Modified Eagle’s Media 
(DMEM)/Ham’s F-12 Media (F12) (ThermoFischer Scientific, Carlsbad, CA), 15% 
Knockout Serum Replacement (ThermoFischer Scientific), 1mM L-glutamine 
(ThermoFischer Scientific), 0.1 mM β-mercaptoethanol (ThermoFischer Scientific), 1% 
minimum essential medium nonessential amino acids (ThermoFischer Scientific), 1% 
penicillin-streptomycin (ThermoFischer Scientific), and 4 ng/mL basic fibroblast growth 
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factor (R&D Systems, Minneapolis, MN). Cells were cultured in a 37°C air humidified 
incubator supplemented with 5% CO2  until 70-80% confluency, at which point they were 
passaged using 1x TrypLE Select (ThermoFischer Scientific). All hESCs used in 
subsequent experiments did not exceed single-cell adaption transfer number 35. 
 
Spin embryoid body (Spin-EB) formation and hemato-endothelial differentiation 
Single-cell adapted hESCs were harvested with 1x TrypLE Select and aggregated 
as spin embryoid bodies, as previously described169,170. In brief, hESCs were plated at 3,000 
cells/100 µL in a round-bottom 96-well plate using serum-free BPEL media supplemented 
with 20 ng/mL BMP4 (R&D Systems), 40 ng/mL SCF (R&D Systems), and 20 ng/mL 
VEGF (R&D Systems) (Stage I media). Cells were centrifuged for 5 minutes at 1500 rpm 
to form embryoid bodies (Day 0) and were incubated for 6 additional days to promote 
mesoderm induction. To differentiate early hemato-endothelial cells, Day 6 spin-EBs were 
transferred to pre-gelatinized 24-well plates (approx. 8-16 EBs/well) with BEL media 
supplemented with 40 ng/mL SCF, 40 ng/mL VEGF, 30 mg/mL thrombopoietin (R&D 
Systems), 30 ng/mL IL-3 (PeproTech, Rocky Hill, NJ), and 30 ng/mL IL-6 (PeproTech) 
(Stage II media). For long-term culture, media was exchanged every 3-4 days with cytokine 
supplementation. To harvest endothelial cells for analysis, non-adherent (hematopoietic) 
cell fractions were removed while the remaining adherent fractions were washed and 
treated with 0.05% trypsin containing 2% chicken serum for 5 minutes. Adherent cells 
were collected, vortexed, and filtered to generate single-cell suspensions suitable for 
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analysis. To harvest hematopoietic cells, only non-adherent cell fractions were harvested 
and filtered to generate single-cell suspensions suitable for analysis. 
 
Immunofluorescent and fluorescent imaging 
To visualize surface antigens on developing endothelial and hematopoietic cells, 
cells were fixed with 3.7% paraformaldehyde for 10 minutes and subsequently 
permeabilized with 0.05% Triton X-100 for 5 minutes, both at room temperature. 
Following permeabilization, cells were initially blocked with immunofluorescence 
blocking buffer (5% goat serum, 1% glycerol, 0.1% bovine serum albumin, 0.1% fish skin 
gelatin, 0.04% sodium azide, pH=7.2) for 30 minutes and then incubated overnight with 
primary antibodies (see below) at 4°C. Cells were then washed and incubated with either 
AlexaFluor 568 or AlexaFluor 647 conjugated anti-mouse secondary antibody 
(ThermoFischer Scientific, Waltham, MA) for 1 hour at room temperature. Following 
subsequent washes, nuclei were counterstained with Hoescht 33342 (Cell Signaling 
Technologies, Danvers, MA) and immediately imaged. Cells were imaged on an Olympus 
IX71 epifluorescent inverted microscope (Olympus, Center Valley, PA). The following 
primary antibodies were used: anti-VWF (Clone 6994, Abcam, Cambridge, MA), anti-
mouse-PECAM1 (Clone 89C2, Cell Signaling Technologies). For GFP and tdTomato 
detection, viable cells were directly imaged in a 24 well plate on an inverted epifluorescent 
microscope in culture medium. 
 
Flow Cytometry and Fluorescent-Activated Cell Sorting 
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Single cells were harvested as previously described and resuspended at 100 
cells/µL of FACS buffer (DPBS + 2% FBS + 0.1% sodium azide). Cells were then 
incubated with antibodies for 30 minutes at 4°C, washed, and resuspended in fresh FACS 
buffer containing Sytox Blue Live/Dead stain. Samples were analyzed immediately on an 
LSR Fortessa cytometer (BD Biosciences, San Jose, CA). The following antibodies were 
used in this study per manufacturer recommendation (all anti-human): CD31-APC 
(eBioscience, San Diego, CA), CD34-PECy7 (BD Biosciences), CD41a-APC (BD 
Biosciences), CD43-APC (BD Biosciences), CD45-APC (BD Biosciences), CD73-APC 
(BD Biosciences), CD144-APC (eBioscience). All gating was set relative to isotype 
controls of identical fluorophores. Data from flow cytometry was analyzed using FlowJo 
software (Treestar, Ashland, OR). 
For cell sorting of hESC-derived hemogenic endothelium (HE) and vascular 
endothelial cells without hematopoietic potential (non-HE), Day 11 hESC-RUNX1c-
tdTomato were differentiated and harvested as described above. Cells were stained with 
anti-human CD41a-APC (BD Biosciences), CD43-APC (BD Biosciences), CD45-APC 
(BD Biosciences), CD73-APC (BD Biosciences), CD144-PECy7 (eBioscience), and 
CD31-APC-eFluor 780 (eBioscience) in sterile FACS Buffer for 30 minutes at 4°C. Cells 
were washed with FACS buffer and dead cells were counterstained with Live/Dead Fixable 
Aqua (ThermoFisher Scientific) immediately prior to sorting. Live HE 
(CD31+CD144+CD41a-CD43-CD45-tdTomato+) and non-HE (CD31+CD144+CD41a-
CD43-CD45-tdTomato-) populations were sorted using a FACSAria II (BD Biosciences) 
directly into BPEL media. Early human hematopoietic progenitor cells (HP) were 
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harvested from a parallel differentiation culture at matched time points. Non-adherent 
hESC-RUNX1c-tdTomato derived cells were harvested as described above and stained 
with anti-human CD34-PECy7 (BD Biosciences) and CD43-APC (BD Biosciences) for 30 
minutes at 4°C. Cells were washed with FACS buffer and dead cells were counterstained 
with Sytox Blue (ThermoFisher Scientific) immediately prior to sorting. Live HP 
(CD34+CD43+tdTomato+) were also sorted on a FACSAria II directly into BPEL media. 
Post-sort flow cytometry sample validation was performed on all samples. 
 
Post-sort HE and non-HE culture conditions 
Immediately following FACS, both HE and non-HE populations were washed and 
counted. To assess for endothelial cell morphology, 5x104 cells were seeded onto 
fibronectin coated 24-well plates in Endothelial Basal Media (EBM2) supplemented with 
EGM-2 BulletKit (Lonza, Allendale, NJ). Following 5 days of culture, cells were washed 
and stained to assess for CD31 expression and morphological appearance using an 
epifluorescent inverted microscope. To assess for hematopoietic potential, 5x104 cells were 
seeded in Stage II media in low-attachment 24-well plates. Following 2 days of cultures, 
cells were directly visualized using an epifluorescent microscope for non-adherent, 
GFP+tdTomato+ hematopoietic cells. Pre-sort cells were also prepared and similarly 
processed as a control for hematopoiesis. 
 
Single-cell capture and RNASeq 
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Sorted HE, non-HE, and HP were stained with a Live/Dead viability/cytotoxicity 
kit (ThermoFisher Scientific) and resuspended at 50 cells/µL. Cells were captured on three, 
separate medium-sized (10-17 µm cell diameter) chips using the Fluidgm C1 Single-Cell 
Auto Prep System (Fluidgm, San Diego, CA) per the manufacturer protocol. Following 
capture, cells were visualized using phase-contrast and fluorescent microscopy using a 
Nikon Inverted Ti-E Deconvolution motorized Microscope (Nikon, Belmont, CA). At this 
point, only live, single, and GFP+ cells were selected for cDNA library preparation. 
Additionally, for HE and HP sorted cells, tdTomato expression was also verified; cells 
absent for tdTomato signal were excluded. Following capture and validation, cDNA was 
prepared from each cell using the SMARTer Ultra Low RNA kit for the Fluidgm C1 
system, according to the manufacturer recommendations (Clontech, Mountain View, CA). 
cDNA library concentrations were assessed using Quant-iT PicoGreen dsDNA assay Kit 
(ThermoFischer Scientific). cDNA concentrations that were less than 25 ng/µL were 
further excluded from subsequent sequencing. mRNA libraries were transcribed using the 
Illumina Nextera XT preparation kit (Illumina, San Diego, CA) according to the 
manufacturer protocol and sequenced on an Illumina HiSeq 2500. Sequencing was 
performed in rapid-mode using 50 bp paired-end reads to a depth of approximately 1.8x106 
reads/sample. In parallel from the same differentiation as single cell captures, bulk 
population RNA controls were also similarly processed and included in subsequent 
analyses. 
 
Bioinformatic analyses of single-cell RNASeq data 
  32 
Illumina reads were processed via a pipeline developed by the University of 
Minnesota Informatics Institute in collaboration with the Minnesota Supercomputing 
Institute and the University of Minnesota Genomics Center. Briefly, FastQ files were 
trimmed using Trimmomatic (Usadel Lab, Max Planck Institute, Germany; parameters 
used: -phred33 -threads 8, ILLUMINACLIP, LEADING:3 TRAILING:3 
SLIDINGWINDOW:4:16 MINLEN:25). After trimming, mapping to the human genome 
was performed via TopHat (v. 2.0.13, Johns Hopkins University) and Bowtie (v. 2.2.4.0, 
Johns Hopkins University). Fraction per kilobases per million (FPKM) expression was 
calculated via cuffquant function in Cufflinks (Trapnell Lab, University of Washington). 
Log-transformed FPKM values were analyzed using the Seurat R toolkit developed by the 
Satija Lab (https://github.com/satijalab/seurat; New York Genome Center, NYU), which 
has been extensively published elsewhere171–174. Principal component analysis (PCA) and 
t-distributed stochastic neighbor embedding (t-SNE) analysis were performed in parallel 
with two gene lists in Seurat; one list of the total genome (“Total”) mapped transcripts 
(26,257 genes) and another restricted list of blood and endothelial (“Blood & EC”; 2,556 
genes) gene subsets. The Blood & EC gene list was exported from a list of genes tagged to 
“hematopoiesis” and “endothelial” categorizers within Ingenuity Pathway Analysis (IPA) 
software (Qiagen, Valencia, CA). For t-SNE analyses, only statistically significant 
principal components (defined as p<0.05, see Supplemental Figure 2-5) for each gene list 
were used as function input. Differentially expressed genes between cell populations and 
clusters were assessed using “ROC” and “t-test” functions in the Seurat package using the 
default settings. Isoform level quantification of RUNX1c was mapped using Salmon (Patro 
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Lab, Stony Brook University)175. FPKM values were averaged between HE and non-HE 
groups and compared to assess RUNX1c enrichment. Gene ontology enrichment analysis 
of the total mapped genes between HE and non-HE was performed using IPA. 
 
Additional Statistical Analyses 
Differences between groups were compared either with student’s t-test using Prism 
6 (GraphPad Software, San Diego, CA). Results were considered statistically significant at 
p-values < 0.05. 
 
RESULTS 
hESC-RUNX1c-tdTomato cells differentiate into early hemato-endothelial cells in 
chemically-defined and xenogenic-free culture conditions 
We first assessed the kinetics of hESC-RUNX1c-tdTomato differentiation into early 
hemato-endothelial cells using defined culture and cytokine conditions (Figure 2-1A). 
Here, we expanded on our previously published data to better identify the emergence of 
endothelial progenitor cells77. hESC-RUNX1c-tdTomato cells differentiated into adherent 
cells with endothelial characteristics as early as Day 9 of culture. Endothelial cells 
propagated around the perimeter of each embryoid body, and were positive for two specific 
endothelial cell markers: CD144 (VE-Cadherin) and von Willebrand Factor (vWF) (Figure 
2-1B, top panels). At Day 12 of differentiation, rounded, non-adherent hematopoietic 
progenitor cells could be seen (Figure 2-1B, bottom panels). These hematopoietic cells all 
expressed a constitutively active GFP:zeo fusion protein, while a fraction of the them also 
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dually expressed tdTomato, suggesting these cells are of the definitive hematopoietic 
lineage and developed from EHT.  
We next quantified the development of endothelial and hematopoietic cells by flow 
cytometry. At Day 9 of culture, a majority of the differentiated cells were endothelial cells, 
defined as CD34+CD31+ (27.5%±6.6) and CD34+CD144+ (22.0%±7.3) with limited 
numbers of hematopoietic progenitor cells, defined by CD34+CD41a+ (2.3%±0.4), 
CD34+CD43+ (6.3%±1.4), and CD34+CD45+ (1.2%±0.6) (Figures 2-1C & 2-1D). By Day 
12, the endothelial cell populations declined, accompanied by a reciprocal increase in 
hematopoietic progenitor cells. By Day 15, a majority of cells were hematopoietic, with 
statically significant gains in the percentage of CD34+CD41a+ (7.16%±2.7, p<0.05), 
CD34+CD43+ (16.17%±3.3, p<0.01), and CD34+CD45+ (11.8%±1.6, p<0.01) phenotypes. 
To parallel hematopoietic development, tdTomato (RUNX1c) was detected in appreciable 
quantity at Day 12 (14.7%±4.1), with a majority of the cells later expressing RUNX1c after 
blood development occurred at Day 15 (69.5%±6.4, p<0.01) (Figures 2-1E & 2-1F). As 
such, hESC-RUNX1c-tdTomato cells serve as an excellent platform to allow us to isolate 
defined endothelial cell populations that are suitable for single-cell genetic analyses. 
 
Combined endothelial cell surface antigen and RUNX1c expression delineate human 
hemogenic endothelium from vascular endothelium lacking hematopoietic potential 
We next assessed for the presence of human hemogenic endothelium from 
differentiating hESC-RUNX1c-tdTomato cells by using a combination of endothelial cell-
specific surface markers and tdTomato+ expression. Because Day 11 was just prior to the 
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onset of detectable RUNX1c hematopoietic cells, we characterized adherent hESC-derived 
cells at this time point. Here, approximately 10% of the total cells were CD144+CD31+ and 
negative for CD41a and CD43 expression (Figure 2-2A, top panels). When sub-gating on 
these populations, we found approximately 40% of the cells were dually tdTomato+, 
suggestive of a hemogenic endothelium phenotype (Figure 2-2A, bottom panels). We next 
FACS-sorted three populations: 1) putative hemogenic endothelial cells (HE; defined as 
CD31+CD144+CD41-CD43-CD45-CD73-tdTomato+); 2) vascular endothelial cells lacking 
hematopoietic potential (non-HE; defined as CD31+CD144+CD41-CD43-CD45-CD73-
tdTomato-) and 3) early hematopoietic progenitor cells (HP; defined as 
CD34+CD43+tdTomato+), and further assessed their phenotypic responses in both 
endothelial cell and hematopoietic cell culture conditions (Figure 2-2B and Supplemental 
Figure 2-1). Here, we demonstrate HE cells retain endothelial morphology in the absence 
of pro-hematopoietic growth conditions. hESC-derived HE seeded onto fibronectin coated 
wells in endothelial growth media were able to generate a confluent, cobblestone 
monolayer that fully expressed CD31 (PECAM1) at the cellular junctions (Figure 2-2C). 
The morphological and phenotypic appearance was similar to that of control human 
umbilical vein endothelial cells (HUVEC). We next assessed whether HE and/or non-HE 
would generate tdTomato+ hematopoietic cells in pro-hematopoietic culture conditions. In 
the span of two days, HE robustly produced non-adherent, tdTomato+ cells similar to pre-
sorted cells from the same hESC differentiation (Figure 2-2D). Additionally, non-HE cells 
failed to produce comparable quantities of tdTomato+ cells, as these cells adhered and 
retained an endothelial-like morphology. Taken together, these results demonstrate that 
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phenotypic HE and non-HE can be sorted and distinguished from hESCs based on this 
combination of endothelial surface antigen and RUNX1c expression. 
 
Single-cell RNASeq reveals similarities in HE and HP gene signatures, but both are 
transcriptionally distinct from non-HE 
Using characterized hESC-derived HE, non-HE, and HP cell populations, we next 
defined each cell population on a single cell transcriptional level. To do so, we performed 
single-cell RNASeq to assess individual cells and determine the developmental similarities 
of each population. We used the Fluidgm C1 Single-Cell Autoprep system in conjunction 
with Illumina Next Generation Sequencing to analyze 55 HE, 47 non-HE, and 35 HP single 
cells (Supplemental Figure 2-2A & 2-2B). To ensure correct identification of single-cells, 
we validated that individual HE and HP cells captured were tdTomato+ within the 
microfluidic capture chamber, while non-HE cells were tdTomato- (Supplemental Figure 
2-2A). We performed sequencing to a depth of approximately 1.8x106 reads/sample to 
further verify enrichment of RUNX1c at the isoform level and provide a complete gene 
expression profile for each individual cell. We first confirmed the representativeness of 
single-cell transcripts to the expression level of the bulk cell populations. As a function of 
fraction per kilobase per million mapped fragments (FPKM), we found a strong correlation 
between gene expression averaged across individual cells as compared to the bulk 
populations (R2=0.90) (Supplemental Figure 2-2C). While we did not see statistically 
significant differences in the expression of all combined transcript variants of the RUNX1 
gene across populations, we confirmed HE possessed higher log-transformed FPKM 
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expression of the RUNX1c specific isoform compared to non-HE (9.23±2.61 vs. 1.22±0.67, 
p<0.01) (Supplemental Figure 2-2D). We next assessed the ontological pathways 
significantly enriched between hESC-derived HE and non-HE using Ingenuity Pathway 
Analysis software. Several of the highest statistically significant ontological pathways 
were specific to embryological development and hematopoiesis, including “Hematological 
System Development and Function” (log p<10-15), “Tissue Development” (log p<10-8), 
“Embryonic Development” (log p<10-7), and “Hematopoiesis” (log p<10-6).  
By generating violin plots of log-transformed FPKM values, we next analyzed the 
expression of key genes known to be associated with vascular endothelial cells, hemogenic 
endothelium, and hematopoietic progenitor cell phenotype. These plots provide 
complementary data regarding total gene expression and the frequency of expression across 
individual cells in a given population. We found that both HE and HP possessed similar 
expression and distribution of several endothelial and hemogenic endothelial genes that 
was higher than those of non-HE. For example, KDR, NR2F2, LMO2, PECAM1, and 
EFNB2 were significantly increased vascular endothelial cell-related genes in the HE and 
HP groups as compared to the non-HE group (Figure 2-3A). SOX17, CDH5, ERG, ESAM, 
FLI1, FOXF1, KIT, and MECOM were also significantly increased hemogenic 
endothelium-related genes in HE and HP as compared to non-HE. We also observed HP 
cells to have overexpression of key hematopoietic genes as compared to HE and non-HE, 
including IL7R, ITGA2B, RAG1, and WNT5A, while some genes such as HOXB5, GATA2, 
GATA3, and MEIS1 were also overexpressed in HE. We further confirmed that genes 
associated with cardiac development and terminal erythroid, myeloid, and lymphoid cell 
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differentiation were not appreciably expressed, while endogenous housekeeper genes, such 
as GAPDH, ACTB, and GPI possessed uniform expression across all three populations 
(Supplemental Figure 2-3). Genes characteristically associated with pluripotency 
(POU5F1/OCT4, NANOG, DPPA2), primitive streak development (MIXL1, T), lateral 
plate mesoderm (FOXF1, IRX3), ectoderm (PAX6, SOX1, SOX10), and endoderm 
(FOXA1A, GATA4) did not yield any detectable FPKM expression (data not shown). 
We next sought to investigate wide-scale transcriptional profile similarities 
between HE, non-HE, and HP populations. Using Seurat, we performed principal 
component analysis to reduce the dimensionality of FPKM expression values using: 1) the 
total mapped gene list (26,257 genes; “Total”) and 2) a hematopoietic and endothelial 
restricted gene list (2,556 genes; “Blood & EC”). In both analyses, we found at least 3 
distinct groups of cells when plotted against the first two most statistically significant 
principal components (Figure 2-3B). In either analysis, many of the HE and HP single cells 
overlapped within a common principal component area, while two clusters primarily 
composed of non-HE cells were distinctly located in separate areas. We further resolved 
the composition of these clusters by performing t-distributed stochastic neighbor 
embedding (t-SNE) analysis using genes assigned only to statistically significant principal 
components for both the Total (Supplemental Figures 2-5A & 2-6A) and Blood & EC 
(Supplemental Figures 2-5B & 2-6B) gene lists. Using this approach, clear resolution of 
one, centralized cluster of transcriptionally similar HE and HP populations could be 
ascertained, while a majority of the non-HE cells were segregated into two divergent 
clusters (Figure 2-3C). In applying Seurat’s density parameter clustering functions, three 
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main clusters (Clusters 2, 3, and 4, with Cluster 1 representing statistical outlier single 
cells) were identified using the total gene list (Figure 2-3D). A similar identification was 
seen in the Blood & EC gene lists in marking Clusters 2, 3, and 5 (note: Cluster 1 represents 
statistical outlier single cells and Clusters 4 and 6 are comprised of ≤3 single cells). In 
analyzing the Total gene list, we observed Cluster 2 was mostly heterogeneous for HE 
(55.8%) and HP (27.91%), with few non-HE cells (16.28%) (Supplemental Figure 2-7). 
Clusters 3 and 4 were mainly composed of non-HE (75.76% and 69.23%, respectively). 
We further validated separation of non-HE from HE and HP by generating heat maps using 
unsupervised clustering of genes found within the statistically significant principal 
components (Figure 2-3E). Taken together, these data demonstrate that individual HE and 
HP are transcriptionally related to one another, while non-HE are heterogeneous and 
transcriptional distinct from both HE and HP. 
 
Clustering analysis identifies novel biomarkers of hESC-derived HE and HP with 
divergent developmental pathways of non-HE 
Using individual cells re-classified into transcriptionally distinct groups from the 
Total gene list, we identified distinguishing biomarkers between HE/HP single cells and 
the two subsets of non-ECs by performing receiver operating characteristic (ROC) curve 
analysis in Seurat. ROC analysis is a non-parametric method that is useful in providing the 
probability (power) that a gene is up- or down-regulated within given group176. Cluster 2 
yielded 651 statistically significant identifier genes, with the most powerful predictors 
being previously known hemogenic endothelium related genes such as CDH5 (DGE: 
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2.07)177, ERG (DGE: 2.08)178, CLDN5 (DGE: 2.07)179, and TEK (DGE: 2.01)180 (Figure 2-
4A). Cluster 3 and Cluster 4 yielded 916 and 928 statistically significant identifier genes, 
respectively. Here, we report the top 50 distinguishing genes between groups of cells 
assigned to Clusters 2, 3, and 4. We next confirmed the specificity of novel biomarkers of 
each cluster by mapping the gene expression to individual cells on the Total gene list t-
SNE plots as shown in Figure 2-3C. We identified at least four novel gene markers with 
increased and specific expression to Cluster 2: TIMP3 (DGE: 2.06), ESAM (DGE: 2.20), 
RHOJ  (DGE: 2.27) and DLL4 (DGE: 2.49) (Figure 2-4B). We also show that TYROBP 
(DGE: 3.78) and CCL4 (DGE: 5.34) are specific in designating the Cluster 3 subset, which 
was largely composed of non-HE. Interestingly, Cluster 4 was mostly comprised of genes 
that encode extracellular matrix protein products. We found significant upregulation of 
COL1A1 (DGE: 6.58), COL1A2 (DGE: 4.63), DCN (DGE: 6.09), LUM (DGE: 4.87), 
COL3A1 (DGE: 3.50), VCAN (DGE: 3.55), and several other extracellular matrix 
components/genes. This would suggest cells of this cluster transformed from an endothelial 
phenotype into a mesenchymal or fibroblast phenotype. To further validate the uniqueness 
of each cluster set, we generated a new heat map of gene expression across individual cells 
using a more stringent approach. We restricted the list of genes to differentially regulated 
genes with high discriminatory power (Power > 0.80) within each cluster (Figure 2-4C). 
This approach indeed generated clear distinctions in global gene expression that was seen 
between individual cells assigned to each cluster. Collectively, our approach has 
established unique genetic biomarkers between hESC-derived HE and non-HE cells, as 
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well as demonstrating a subset of non-HE are capable of further transformation away from 
an endothelial cell lineage. 
 
DISCUSSION 
In the present study, we utilized hESCs harboring a RUNX1c-tdTomato reporter to 
assess the phenotypic and transcriptional profiles of the earliest definitive hemato-
endothelial cells. In conjunction with endothelial-cell specific immunophenotyping and 
RUNX1c expression, we identified hESC-derived HE that not only maintained vascular 
morphology in endothelial culture conditions, but also differentiated RUNX1c+, non-
adherent, hematopoietic progenitors when cultured in the presence of hematopoietic 
cytokines. Furthermore, through next generation sequencing of individual hemogenic 
endothelial cells, vascular endothelial cells lacking hematopoietic potential, and the earliest 
definitive hematopoietic progenitor cells, we determined that hESC-derived HE and HP 
are transcriptionally similar to each other, but distinct from a heterogeneous population of 
non-HE. We also identify several novel candidate genes that serve to distinguish HE from 
non-HE populations. 
To date, there have been few reports fully characterizing the complete development 
of undifferentiated hESCs/hiPSCs through hemogenic endothelium to the generation of 
HSPCs. Many reports have relied on cell immunophenotyping alone, which has been useful 
in elucidating key differences between human endothelial and the first formed 
hematopoietic cells. For example, Nakajima-Takagi et al.70 separated endothelial cells 
from the earliest hematopoietic progenitor cells (termed “pre-HPCs”) simply based upon 
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CD34+CD43- and CD34+CD43+CD45-/lo. With this strategy, they discovered SOX17 was 
overexpressed in human hemogenic endothelium as compared to pre-HPCs and matured 
hematopoietic cells, and thus a key regulator of hematopoietic development. Indeed, we 
observed similar overexpression of SOX17 in a majority of cells within our HE population 
as compared to the HP population. We now provide complementary data that SOX17 is not 
expressed in endothelial cells lacking hematopoietic potential. Our finding parallels studies 
in the mouse model, in which knockout of SOX17 abolished the definitive hematopoietic 
program (loss of T-lymphocyte potential), but did not alter expression levels of EphrinB2 
(human homolog: EFNB2) or Coup-TfII (human homolog: NR2F2), genes that are 
associated with arterial and venous endothelium specification, respectively69,71.  
Choi et al.157 and Raffi et al.150 both used more specific hemato-endothelial 
phenotypes, relying on CD31+, CD34+, CD117+, CD144+, and CD73- to detect endothelial 
cells and CD41a+, CD43+, CD235a+ to monitor hematopoietic development. While both 
studies provide convincing evidence for a precursor endothelial population that directly 
supports hematopoietic development, it is unclear as to which phase of hematopoiesis 
(primitive vs. definitive) these earliest cells arise from. Primitive hematopoiesis is thought 
to primarily originate from hemangioblasts, which are bi-potent cells able to differentiate 
only into embryonic vasculature cells or transient erythroid/myeloid cells. Hemangioblasts 
are almost identical in their endothelial surface antigen expression as hemogenic 
endothelium79,181–184. As such, our described system that is co-dependent on endothelial 
positive-selection (CD31+CD144+CD73-) and RUNX1c expression provides more precise 
specification of the definitive hematopoietic program leading to a more resolved 
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understanding of the events preceding HSPC development. Indeed, a related approach has 
recently been verified in an elegant study by Ditadi, et al95. Here, human hESC-derived 
hemogenic endothelium restricted to an adherent CD34+CD73-CD184-RUNX1c+ 
population were able to generate RUNX1c+ hematopoietic cells with T-lymphocyte 
potential. Furthermore, combinations of CD184 (CXCR4), CD73, and RUNX1c could be 
used as molecular labels in distinguishing the acquisition of either an arterial or venous 
phenotype from vascular endothelial progenitor cells. Moving forward, it is clear both cell 
surface and genetic identifiers must be used to adequately define and resolve specialized 
subsets from a heterogeneous collection of differentiating hemato-endothelial cells. 
Our single-cell RNASeq experiments revealed several novel candidate markers that 
were specific to human hemogenic endothelium and definitive hematopoietic progenitor 
cells. TIMP3, ESAM, RHOJ, and DLL4 were found to possess some of the highest 
discriminatory powers for distinguishing HE and HP from non-HE (Figure 2-4B). TIMP3 
(tissue inhibitor of metalloproteinase-3), while not previously implicated in developmental 
hematopoiesis, has previously been shown to play an important role in HSPC proliferation 
by recruiting quiescent hematopoietic stem cells into the cell cycle185,186. ESAM 
(endothelial cell selective adhesion molecule) has been identified (albeit in the mouse) as 
a reliable marker for long-term repopulating hematopoietic stem cells derived from the 
aorta-gonad-mesonephros region that also possessed lymphoid potential187,188. Moreover, 
ESAM expression is maintained throughout the transition of hematopoiesis to the bone 
marrow and its expression is increased during the aging process. Because ESAM was highly 
expressed in almost every HE and HP single cell we analyzed (Figure 2-3A), it represents 
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a potential candidate for hemogenic endothelial cell selection and/or overexpression 
studies to engineer hematopoietic progenitors from hESCs with hemato-lymphoid 
potential. RHOJ encodes a Rho GTPase that is normally restricted to vascular endothelial 
cells. RHOJ expression, as well as other key hemogenic endothelial proteins, such as VE-
cadherin, endoglin, and vWF, are regulated upstream by ERG, which is further implicated 
in hESC differentiation into endothelial cells178,189–191. We observed overexpression of both 
RHOJ and ERG in our HE and HP populations. Interestingly, hyperactivation of RhoJ 
enhances endothelial cell focal adhesion disassembly and increases the mobility of 
endothelial cells192. Thus, a similar mechanism may be crucial during EHT to convert 
adherent endothelial cells into non-adherent and free-moving HSPCs. Lastly, EHT and 
definitive hematopoiesis have been hypothesized to be evolutionary Notch-
dependent30,95,193,194. DLL4 is a downstream mediator of VEGF activity and induces the 
upregulation of Notch1 and its effector targets. DLL4 is highly enriched in the vascular 
niche and has recently been shown to support the production of partially engraftable CD34+ 
cells derived from non-human primate induced pluripotent stem cells93. Consequently, 
enrichment of DLL4 may serve as a useful method for identifying hemogenic endothelial 
cells derived from hESCs. 
We also looked at other key transcriptional regulators of human EHT that have been 
recently reported from bulk cell sequencing. Dou et al.68 provided insight that medial 
HOXA genes are silenced in hESC-derived hemato-endothelial cells, but were critical for 
fetal-liver HSPC expansion and maintenance. In corresponding fashion, we found no 
appreciable expression of any HOXA locus genes in our hESC-derived hemato-endothelial 
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cell populations, which is consistent with our prior analyses77 (Supplemental Figure 2-8A). 
Interestingly, we observed significant increases in HOXB locus gene expression between 
hESC-derived HE/HP and non-HE populations, specifically in HOXB3, HOXB5, HOXB6, 
and to an extent, HOXB7 (Supplemental Figure 2-8B). HOXB5 has been recently described 
(albeit in mouse) to be expressed during EHT and defines HSCs with long-term 
engraftment potential195. As such, HOXB genes may be of higher biological importance in 
conferring hemogenic potential from hESC/hiPSC-derived hemogenic endothelium. 
By assessing the transcriptional repertoire of individual cells, we also revealed 
heterogeneity in non-HE cells. Although all non-HE expressed traditional endothelial cell-
specific surface antigens, a small subset of non-HE were heavily enriched with genes 
encoding extracellular matrix proteins (Cluster 4, Figure 2-4A). This genetic signature 
highly suggests transformation from an endothelial lineage to a mesenchymal or stromal 
cell lineage in a developmental process known as the endothelial-to-mesenchymal 
transition (EndMT). EndMT primarily is a TGF-β driven process that normally is required 
for intimal thickening and stabilization of vasculature during embryonic vasculogenesis196. 
Other groups have reported that hESC- and hiPSC-derived endothelial cells are highly 
susceptible to EndMT, particularly following long-term passaging and cell culture196–198. 
This, in part, may be due to a combination of defined factors within culture media and/or 
also the cellular origin of hiPSCs used. Our results suggest that a small degree of EndMT 
occurs even at the earliest development of hemato-endothelial cells from embryoid bodies 
(Figure 2-5). As such, it may be imperative to negatively select against these transitioning 
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cells to prevent the out-crowding of true vascular endothelial cells and/or hemogenic 
endothelial cells. 
Lastly, it is an important distinction that we used a human platform to analyze the 
transcriptional profiles of single cells as they commit towards hemato-endothelial lineages 
at the earliest stage of hematopoiesis. Our findings share many commonalities to a related 
single-cell approach investigating mouse hemogenic endothelium46. Using a pan-RUNX1 
mouse reporter model and single-cell qRT-PCR, Swiers et al. demonstrated mouse 
hemogenic endothelium was also enriched for key endothelial and hematopoietic specific 
genes simultaneously, similar to what we observed with human HE. Here, they concluded 
hemogenic endothelium transitions away from an endothelial repertoire and towards a 
distinct hematopoietic repertoire through analysis of matured hematopoietic cell 
populations (CD41+ and CD45+). Our findings in which the very first developed human 
hematopoietic cells (CD34+CD43+RUNX1c+)199 are transcriptionally similar to hemogenic 
endothelium complements this working model of EHT. This also lends credence to 
pursuing future gain and/or loss of function studies using candidate genes described herein 
within hESCs to optimize the development of hemogenic endothelium. These studies 
would provide further mechanistic insight into the key molecular drivers regulating the 
development of multipotent and potentially engraftable human HSPCs. 
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Figure 2-1. hESC-RUNX1c-tdTomato cells can model the human endothelial-to-
hematopoietic transition (EHT) in vitro. (A) Schema of hemato-endothelial 
differentiation from hESC-RUNX1c-tdTomato cells as spin embryoid bodies (spin-EB). 
(B) Top; Representative immunofluorescent images of hESC-RUNX1c-tdTomato at Day 9 
of differentiation for endothelial specific surface antigens CD144 and vWF (red). 
Magnification 4x and 10x (inset) are shown. Nuclei are counterstained with DAPI (blue). 
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Representative immunofluorescent images of hESC-RUNX1c-tdTomato at Day 12 of 
differentiation demonstrating development of non-adherent, dual constitutive GFP+ (green) 
and tdTomato+ (red) reporter hematopoietic cells from spin-EBs (bottom panels). 
Magnification 20x. (C) Representative flow cytometry plots of endothelial (CD31, CD144) 
and early hematopoietic surface antigens (CD41a, CD43, CD45) at Day 9 (D9), Day 12 
(D12) and Day 15 (D 15) time points over the course of hESC-RUNX1c-tdTomato 
differentiation. (D) Quantification of flow cytometry as shown in panel C. *p<0.05, 
**p<0.01 as compared to Day 9 assessed by student’s t-test. Each data point represents a 
distinct hESC-RUNX1c-tdTomato differentiation and errors bars represent SEM; n=4-7 (E) 
Representative flow cytometry plots of tdTomato (RUNX1c) expression at Day 9 (D9), 
Day 12 (D12) and Day 15 (D 15) time points over the course of hESC-RUNX1c-tdTomato 
differentiation. (F) Quantification of flow cytometry as shown in panel E. **p<0.01 as 
compared to Day 9 assessed by student’s t-test, error bars represent SEM; n=4-7. 
  50 
 
Figure 2-2. Functional human hemogenic endothelium can be phenotypically 
identified and sorted from hESC-RUNX1c-tdTomato cells. (A) Representative flow 
cytometry plots of differentiating hESC-RUNX1c-tdTomato cells at Day 11 expressing 
typical endothelial surface antigens (CD144+CD31+), but absent for early hematopoietic 
surface antigens (CD144+CD41a-, CD144+CD43-). Phenotypic endothelial cells were gated 
(top panel) and assessed for tdTomato expression (bottom panel). A fraction of endothelial 
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cells were tdTomatodim (red histogram) as compared to control hESCs lacking the GFP-
RUNX1c-tdTomato reporter (blue histogram), consistent with the identification of 
hemogenic endothelium. n=2 independent differentiations. (B) Schema of FACS sorting 
hESC-RUNX1c-tdTomato cells into hemogenic endothelium (HE), endothelial cells that 
lack hematopoietic potential (non-HE), and early hematopoietic progenitor cells (HP). (C) 
Sorted HE cells seeded on fibronectin-coated wells with EGM-2 media for 5 days and 
subsequently immunofluorescently imaged for CD31 (left column). HE stained positive 
for CD31 (purple), GFP (green), and were tdTomatodim (red) while retaining a stereotypical 
cobblestone morphology of traditional endothelial cells. Untransfected human umbilical 
vein endothelial cells (HUVECs) are shown as an endogenous control (right column). (D) 
Presorted hESC-RUNX1c-tdTomato-derived adherent cells, sorted HE, and sorted non-HE 
were plated in Stage II hemato-endothelial differentiation media for two additional days to 
promote hematopoiesis. Both Presort and HE populations robustly generated non-adherent 
GFP+tdTomato+ hematopoietic progenitor cells, while non-HE did not adequately support 
hematopoietic development. Underlying non-HE cells further retain their endothelial 
morphology. Bar=100µm. 
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Figure 2-3. Single-Cell RNASeq of hESC-RUNX1c-tdTomato hemato-endothelial 
cells reveals distinct transcriptional networks between HE and non-HE. (A) 
Distribution of the fraction per kilobases per million (FPKM) reads mapped for 
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characteristic endothelial, hemogenic endothelium, and hematopoietic genes from HE, 
non-HE, and HP cells. Values along the vertical axis represents the log-transformed FPKM 
expression of each single cell sequenced, while the width of the violin indicates the 
frequency of cells at a particular FPKM level. (B) Principal component projections of the 
first and second statistically significant principal components for all 137 cells sequenced. 
PCA was performed using the entire mapped human genome sequence (Total; left panel) 
as well as a restricted gene list specific for known endothelial and hematopoietic genes 
(Blood & EC; right panel). Each data point represents the dimensionally reduced gene 
expression data for a single cell. (C) t-distributed stochastic neighbor embedding (t-SNE) 
plots of all 137 cells for Total (left) and Blood & EC (right) gene sets. (D) Statistically 
distinct clusters that originated from t-SNE dimensionality reduction shown in Panel C 
were computationally labelled and reclassified as belonging to a transcriptionally distinct 
population. Cluster 1 (red dots) are cells that failed to orient into one of the defined clusters 
(Cluster 2: green, Cluster 3: cyan, or Cluster 4: purple for the Total gene set; Cluster 2: 
yellow, Cluster 3: green, Cluster 4: cyan, or Cluster 5: blue for the Blood & EC gene set). 
(E) Heat map of Total gene expression defined within projected and statistically significant 
principal components (see Supplemental Figure 2-5A). Horizontal rows represent z-score 
expression of log-transformed FPKM values while vertical columns represent each single 
cell. 
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Figure 2-4. hESC-RUNX1c-tdTomato-derived non-HE are heterogeneous and can be 
distinguished from HE and HP using defined gene signatures. (A) Lists of the top 50 
differentially expressed genes that distinguish cells assigned in Cluster 2, 3, and 4 as shown 
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in Figure 2-3D from the Total gene set. Gene screening was assessed by ROC analysis, 
with the average differential gene expression (Avg. DGE) and ROC classification power 
(0=random, 1=perfect correlation) for each gene listed; genes are ranked by their cluster 
distinguishing potential. (B) Gene expression superimposed onto Total t-SNE plots (Figure 
2-3D) to reflect uniqueness to a cluster subset. Novel identifying biomarkers, such as 
TIMP3 and ESAM possess high expression within cells of Cluster 2 (mainly HE/HP), while 
TYROBP and CCL4 are uniquely expressed in Cluster 3 (non-HE), and ECM genes such 
as COL1A1 and VCAN are expressed in a distinct subset of non-HE cells within Cluster 4. 
(C) Heat map of differentially regulated marker genes as defined by cell clustering in Panel 
A. Individual cells assigned to each cluster are plotted on the vertical axis. 
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Figure 2-5. Working model of human pluripotent stem cell EHT in vitro. 
Undifferentiated hESCs/hiPSCs first develop towards mesodermal lineages and generate 
CD34+ progenitor cells with dual hemato-endothelial potential. CD34+ cells subsequently 
differentiate into endothelial cells that possess hematopoietic potential (HE) or endothelial 
cells that lack endothelial potential (non-HE). HE cells can then differentiate further into 
hematopoietic progenitor cells in a process known as EHT. A subset of non-HE can 
subsequently transform into other cells of mesenchymal lineages, such as a mesenchymal 
stem cell or fibroblast, in a process known as the endothelial-to-mesenchymal transition 
(EndMT). 
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Supplemental Figure 2-1. FACS sorting strategy of Day 11 hESC-RUNX1c-
tdTomato-derived cells. (A) Representative flow cytometry plots used to distinguish HE 
from non-HE within the adherent fraction of hESC-RUNX1c-tdTomato cells. Day 24 non-
adherent hematopoietic cells also derived from hESC-RUNX1c-tdTomato cells in a parallel 
differentiation are also shown to establish positive gating controls of tdTomato expression. 
(B) Representative flow cytometry plots used to sort early hematopoietic progenitor cells 
from the non-adherent fraction of hESC-RUNX1c-tdTomato cells.  
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Supplemental Figure 2-2. Fluidgm C1 Capture and quality control of single-cell 
RNASeq data. (A) Representative images of 96-well microfluidic capture chambers, 
which served as the initial point of cell quality control. Within each fluidic capture point, 
cells were assessed for 1) singularity, 2) GFP+ expression, and 3) absence of red-fluorescent 
ethidium homodimer-1 stain (dead stain). Furthermore, HE and HP sorted populations were 
validated for tdTomatodim expression, while non-HE were validated for tdTomato- 
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expression. Cells that failed these quality control criteria were excluded from cDNA library 
preparation. (B) Statistics of Fluidigm C1 capture and HiSeq 2500 sequencing. A total of 
55 HE, 47 non-HE, and 35 HP were considered validated for subsequent analyses. (C) 
Total gene expression across individual cells were plotted and compared to the gene 
expression of similarly collected bulk RNASeq sample controls. R2=0.90. Each dot 
represents a single gene, while the blue cloud surrounding each gene reflects the variance 
across individual cells. (D) log-transformed FPKM values for the RUNX1c isoform 
averaged across all cells in HE and non-HE populations. **p<0.01 as compared to HE and 
assessed using student’s t-test, error bars represent SEM. (E) Top 15 canonical pathways 
derived from the Ingenuity Pathway Analysis gene ontology algorithms for the HE and 
non-HE populations. 
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Supplemental Figure 2-3. Supplemental violin plots of single-cell RNASeq gene 
expression. Log-transformed FPKM values of key genes associated with cardiovascular 
development, erythroid, lymphoid, and myeloid cell phenotypes. Traditional housekeeper 
gene expression (GAPDH, ACTB and GPI) are also shown to demonstrate homogeneous 
expression and frequency across HE, non-HE, and HP populations. 
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Supplemental Figure 2-4. Dispersion plots reveal variable genes across individual 
cells. (A) Dispersion (Variance of gene expression across single cells/average of gene 
expression) as a function of average gene expression (log (FPKM+1)) across all individual 
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for the total gene list and (B) blood and endothelial gene subset list. Black points with blue 
hues represent the mean expression of a gene, while dashed contours represent the density 
of single cells as obtained using Seurat’s default density estimation settings. Genes of 
significant variability across sample populations are labeled with the gene symbol and 
number of variable genes is listed in the bottom right corner. These genes were included 
for initial PCA clustering algorithms. 
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Supplemental Figure 2-5. Significance level of principal components. Output of Seurat 
p-value calculations of principal components as assessed from the (A) total gene list and 
(B) blood and endothelial gene restricted subset list. In brief, significance testing of 
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principal components is assessed by Jackstraw analysis200. Each subplot compares p-values 
of genes within the principal component via Jackstraw analysis (horizontal axis) as 
compared to a theoretical p-values from a random population sampling (vertical axis). 
Principal components with p<0.05 were subsequently used in t-SNE analysis and clustering 
classifications as described in Figure 2-3D. 
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Supplemental Figure 2-6. Gene identification from statistically significant principal 
components. Visualization of principal component scores and gene symbol from each 
statistically significant principal component identified in Supplemental Figure 2-5 for (A) 
total gene list and (B) blood and endothelial gene restricted list subset. 
  66 
 
Supplemental Figure 2-7. Cell identification of distinct clusters as determined by t-
SNE analysis. Cells assigned to cluster 2, 3, and 4 from the Total gene list t-SNE analysis 
are listed based on original single-cell sequencing classification. Cluster 2 comprises a 
majority of HE while Clusters 3 and 4 both comprise a majority of non-HE. 
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Supplemental Figure 2-8. Violin plots of single-cell RNASeq expression of HOXA and 
HOXB locus genes. A) Log-transformed FPKM gene expression values for HOXA locus 
genes. Genes that did not have any detectable level of expression are listed as “not-
expressed.” B) Log-transformed FPKM gene expression values for HOXB locus genes. 
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CHAPTER 3 
 
Aryl hydrocarbon receptor inhibition promotes hemato-lymphoid development from 
human pluripotent stem cells 
  69 
ABSTRACT 
The aryl hydrocarbon receptor (AHR) plays an important physiological role in 
hematopoiesis. AHR is highly expressed in hematopoietic stem/progenitor cells (HSPCs) 
and inhibition of AHR results in a marked expansion of human umbilical cord blood-
derived HSPCs following cytokine stimulation. It is unknown whether AHR also 
contributes earlier in human hematopoietic development. To model hematopoiesis, human 
embryonic stem cells (hESCs) were allowed to differentiate in defined conditions in the 
presence of the AHR antagonist StemReginin-1 (SR-1) or AHR agonist 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). We demonstrate a significant increase in 
CD34+CD31+ hemato-endothelial cells in SR-1 treated hESCs, as well as a two-fold 
expansion of CD34+CD45+ hematopoietic progenitor cells. Hematopoietic progenitor cells 
were also significantly increased by SR-1 as quantified by standard hematopoietic colony-
forming assays. Using a CRISPR/Cas9 engineered hESC-RUNX1c-tdTomato reporter cell 
line with AHR deletion, we further demonstrate a marked enhancement of hematopoietic 
differentiation relative to wild-type hESCs. We also evaluated whether AHR antagonism 
could promote innate lymphoid cell differentiation from hESCs. SR-1 increased 
conventional natural killer (cNK) cell differentiation, whereas TCDD treatment blocked 
cNK development and supported Group 3 innate lymphoid cell (ILC3) differentiation. 
Collectively, these results demonstrate AHR regulates early human hemato-lymphoid cell 
development and may be targeted to enhance production of specific cell populations 
derived from human pluripotent stem cells. 
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INTRODUCTION 
Human pluripotent stem cells function as an important model system to elucidate 
basic genetic and cell signaling mediators of human hematopoietic development201–203. 
Previous studies demonstrate development of erythroid155,156, myeloid89,158,159,204, and 
lymphoid78,160,161 cells from human embryonic stem cells (hESCs) and human induced 
pluripotent stem cells (hiPSCs). However, the molecular regulation of earlier human 
hematopoietic stem and progenitor cells (HSPCs) from pluripotent stem cells remains less 
well understood. Functional HSPCs develop during the definitive stage of hematopoiesis 
directly from specialized hemogenic endothelium in a process known as the endothelial-
to-hematopoietic transition (EHT)18,28. Hemogenic endothelium capable of EHT has been 
identified from hESCs/hiPSCs and can thus be used as a platform to investigate the 
mechanistic cues supporting human HSPC development78,157,205. 
The aryl hydrocarbon receptor (AHR) is a member of the PAS (Per/Arnt/Sim) 
family of environment-sensing, basic helix-loop-helix transcriptional regulators that is well 
known for its ability to mitigate reactive oxygen species due to extracellular stressors. 
However, there is increasing evidence for an important physiological role of AHR in 
hematopoiesis145. AHR mRNA and protein are enriched in both murine and human HSPCs, 
with a significant reduction in expression at the onset of HSPC proliferation130,206. Ahr 
knock-out mice yield an increased number of bone-marrow derived Lin-Sca+Kit+ HSPCs 
that are hyperproliferative and have an increased propensity for leukemogenesis143. This 
finding has been extended to human HSPCs through directed small molecule targeting of 
AHR in CD34+ umbilical cord blood (UCB). Treatment with StemReginin-1 (SR-1), a 
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potent human-specific antagonist of AHR, substantially increases the proportion of 
engraftable UCB CD34+ cells while also sustaining hematopoietic multipotency207. This 
strategy has recently been used in clinical trials that demonstrate dramatic HSPC expansion 
and an improved time to neutrophil engraftment following transplantation with SR-1 
expanded UCB142. 
While these results confirm the integral role of AHR in the maintenance of HSPCs, 
there are a paucity of studies investigating what function, if any, AHR has in the initial 
differentiation of hematopoietic cells from mesodermal and endothelial progenitor cells. 
Here, we utilize hESCs differentiated in chemically-defined conditions to test the 
hypothesis that AHR regulates early human hematopoietic development at the stage of 
EHT. We demonstrate inhibition of AHR using SR-1 or deletion of AHR using 
CRISPR/Cas9 leads to increased hemato-endothelial and functional hematopoietic 
progenitor cell differentiation. Additionally, we provide novel evidence that AHR 
inhibition also improves development of conventional natural killer (cNK) cells from 
hESCs, while AHR hyperactivation supports Group 3 innate lymphoid cell (ILC3) 
differentiation. Collectively, these studies demonstrate AHR inhibition enhances both early 
human HSPC and lymphoid development, and this strategy may be useful to improve the 
quantity and homogeneity of clinically useful hematopoietic cell populations derived from 
human pluripotent stem cells. 
 
METHODS 
Hemato-endothelial differentiation of hESCs 
  72 
Single-cell adapted hESCs (H9) were maintained on irradiated mouse embryonic 
fibroblasts (MEF) in ES growth media, as previously described77. hESCs were allowed to 
differentiate as spin-embryoid bodies (EBs) as previously described (Figure 3-1A)77,170. In 
brief, hESCs were plated at 3,000 cells/100 µL in a round-bottom 96-well plate using 
serum-free BPEL media supplemented with 20 ng/mL BMP4, 40 ng/mL SCF, and 20 
ng/mL VEGF (all R&D Systems, Minneapolis, MN). Cells were centrifuged to form 
embryoid bodies (defined as Day 0) and were incubated for 6 additional days (defined as 
Day 6) to promote mesoderm induction. To differentiate early endothelial and 
hematopoietic progenitor cells, Day 6 EBs were transferred to pre-gelatinized 24-well 
plates (approx. 8-16 EBs/well) with BEL media supplemented with 40 ng/mL SCF, 40 
ng/mL VEGF, 30 mg/mL thrombopoietin (all R&D Systems), 30 ng/mL IL-3, and 30 
ng/mL IL-6 (both PeproTech, Rocky Hill, NJ). To modulate AHR activity, EBs were 
treated at Day 6+0 with DMSO, 1 µM SR-1 (Cellagen Technologies, San Diego, CA), or 
10 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Sigma-Aldrich, St. Louis, MO). 
Media was exchanged every 3 days with small molecule and cytokine supplementation. At 
indicated time points, non-adherent cell fractions were collected and saved while the 
remaining adherent fractions were treated with 0.05% trypsin containing 2% chicken 
serum. Adherent cells were combined with the non-adherent fractions for analysis, unless 
otherwise stated. 
 
Innate lymphoid cell (cNK cell and ILC3) differentiation from spin-EBs 
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Spin-EBs were generated as described above122,160,161. Following 11 days of 
mesoderm conditioning (Day 11), spin-EBs were collected and analyzed by flow cytometry 
to assess hematopoietic progenitor cell potential (see flow cytometry methods for 
antibodies used) (Figure 4A). Spin-EBs yielding >30% CD34+CD45+ cells were 
transferred onto 24-well plates coated with irradiated OP9-DL1 cells208,209 (now defined as 
Day 11+0). EBs and OP9-DL1 were co-cultured in NK differentiation media (NKDM) 
supplemented initially with SCF, IL-15, IL-7, Flt3-L (all R&D Systems), and IL-3 
(PeproTech) for one week; DMSO, SR-1, or TCDD were also added at Day 11+0. Every 
week, a one-half media change with NKDM supplemented with SCF, IL-15, IL-7, Flt3-L, 
and drugs was performed. hESCs were differentiated for four additional weeks (Day 
11+28) and non-adherent cells were harvested for analysis. 
 
Hematopoietic colony-forming unit (CFU) assay 
Day 6+5 spin-EB non-adherent fractions were resuspended in IMDM. 50,000 cells 
were seeded in 2 mL of H4436 Methocult (StemCell Technologies, Vancouver, CAN) and 
plated directly in 35 mm culture dishes (Greiner, Monroe, NC). Plates were incubated for 
14 days and subsequently counted and phenotypically scored using standard criteria89.  
 
CRISPR-Cas9 gene editing and hESC transfection 
gRNA against AHR exon 1 (5’-TCAGATTGTCCCTGGAGGTC-3’) driven by U6 
promoter was subcloned into a pCR4-TOPO vector (ThermoFisher Scientific). Single-cell 
cell adapted H9 RUNX1c-tdTomato reporter cell lines previously produced by our group77 
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were transfected with 1 µg plasmid DNA, 1 µg Cas9 mRNA (TriLink Biotechnologies, 
San Diego, CA), and mCherry fluorescent protein mRNA using the Neon Transfection 
System (ThermoFisher Scientific) set at 1100V, 20ms, 1 pulse. Post-transfection, cells 
were resuspended in MEF conditioned media without antibiotics supplemented with 5 µM 
Y-27632 and seeded onto Matrigel-coated 6 well plates. 96-hour post-transfection, 
individual mCherry+ colonies were picked onto fresh MEFs for clonal expansion. Genomic 
DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen) and AHR PCR 
products were generated with high fidelity AccuPrime Taq DNA Polymerase 
(ThermoFisher Scientific). PCR products were purified and subcloned into a pCR-TOPO4 
vector for sequencing. Cloned products were transformed into One Shot TOP10 competent 
cells (ThermoFisher Scientific) and were colony sequenced via rolling circle amplification 
(Sequetech, Mountain View, CA) using M13R primers. On- and off-target effects were 
assessed using a Surveyor mutation detection kit (IDT Technologies, Coralville, IA) and 
the following AHR-specific primers: F: 5’- AGGCAGCTCACCTGTACT-3’; R: 5’: 
CATCTCGCCTTACCAAACTCTAC-3’. Only clones that displayed AHR specific 
cleavage products and had AHR Exon 1 specific deletions as determined by sequencing 
were chosen for experiments. 
 
Flow Cytometry 
The following additional antibodies were used (all anti-human): LFA-1 
(CD11a/CD18)-APC-R700 (BD Biosciences), CD31-APC (eBioscience), CD33-APC (BD 
Biosciences), CD34-PECy7 (BD Biosciences), CD34-APC (BD Biosciences), CD41a-
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APC (BD Biosciences), CD43-APC (BD Biosciences), CD45-APC (BD Biosciences), 
CD56-PECy7 (BD Biosciences), CD56-BV421 (BD Biosciences), CD94-PerCP-Cy5.5 
(BD Biosciences), CD117-PECy7 (BD Biosciences), CD117-APC (eBiosciences), 
CD144-APC (eBioscience). Samples were analyzed on either an LSRFortessa or LSRII 
flow cytometer (BD Biosciences). Gating was set relative to isotype controls of identical 
fluorophores. Data from flow cytometry was analyzed using FlowJo software (Treestar, 
Ashland, OR). 
 
FACS sorting and CD34+ cell expansion 
Non-adherent cells from Day 6+5 spin EBs were washed, filtered, and stained with 
anti-human CD45-PECy7 (eBioscience) and CD34-APC (BD Biosciences) in FACS 
Buffer (DPBS + 2% FBS and 0.1% sodium azide) for 30 minutes at 4°C. Dead cells were 
counterstained with Sytox Blue (ThermoFisher Scientific) immediately prior to sorting. 
Live CD34+CD45+ populations were sorted using a FACSAria II (BD Biosciences). 
Human UCB CD34+ cells (ClinImmune Lab, Denver, CO) were sorted using MACS 
separation columns and CD34+ microbead kit (Miltenyi Biotec). Immediately post-sort, 
cells were cultured with Flt-3L, SCF, TPO, and IL-6 (all 100 nM) as described elsewhere141 
and supplemented with DMSO, SR-1, or TCDD. Cells were counted every 3 days and 
assessed for CD34 expression by flow cytometry. Total CD34+CD45+ cell count was 
determined by multiplying the absolute cell count by the percentage of CD34+CD45+ cells 
remaining. 
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Cell cycle analysis and proliferation studies 
Spin EBs were differentiated into hemato-endothelial cells with non-adherent 
cells harvested on Day 6+5. Cells were cultured in a 24-well plate and harvested after 1 
week for flow cytometry analysis. Cells were co-stained with anti-human CD34-PECy7 
to monitor proliferation of HSPCs. For cell cycle analysis, Day 6+5 non-adherent cells 
derived from EBs were harvest and monitored for S-phase using the Click-iT EdU Alex 
Fluor 647 flow cytometry assay kit per manufacturer instructions. Prior to flow 
cytometry, cells were counterstained with 50 µg/mL propidium iodide supplemented with 
100 µg/mL RNAse A (New England BioLabs, Ipswich, MA). 
 
RNA isolation and quantitative real-time PCR (qRT-PCR) analysis 
Non-adherent cell fractions were harvested as previously described in the main 
text. Total RNA was harvested using the Qiashredder tissue homogenizer kit (Qiagen, 
Valencia, CA) with RNAeasy Mini Kit. RNA concentration and purity was assessed 
using a NanoDrop 2000 (ThermoFisher Scientific) spectrophotometer and subsequently 
revere transcribed with a SensiFAST cDNA Synthesis Kit (Bioline, Taunton, MA). qPCR 
was performed using the All-in-One qPCR Mix (GeneCopoeia, Rockville, MD) and 
cDNA was used at 50 ng/uL per reaction for qRT-PCR using gene specific human primer 
pairs (Supplementary Table 1). qPCR reactions were run on an StepOnePlus Real-Time 
PCR System thermocycler (ThermoFisher Scientific) in either technical duplicate or 
triplicate. Ct values were normalized to a GAPDH housekeeper for each sample. Data 
were then normalized relative to controls using the 2^-(ΔΔCt) method. 
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Immunoblotting 
Undifferentiated hESCs were harvested and lysed in lysis buffer (10mM HEPES 
pH 7.4, 150 mM KCl, 0.1% NP40, 5mM MgCl2 supplemented with EDTA-free protease 
inhibitor tablet (Roche, Branchburg, NJ)) overnight at 4°C. Protein concentration was 
determined by bicinchoninic acid (BCA) assay, per manufacturer protocol (ThermoFisher 
Scientific). 50 µg of protein lysate was added to 6x SDS loading buffer (250mM Tris, 2% 
SDS, 20% glycerol, 0.05% bromphenol blue), loaded onto a 4-20% Mini-PROTEAN 
TGX Gel (BioRad, Hercules, CA), and electrophoresed at 120V for 1 hour. Protein was 
then transferred to a nitrocellulose membrane in transfer buffer (25x Tris-Glycine transfer 
buffer with 5x 100% methanol) overnight at 30V. Membranes were blocked with 5% 
milk for 1 hr at room temperature and subsequently incubated with the following primary 
antibodies overnight at 4°C in blocking buffer (all human): mouse monoclonal anti-AHR 
(ab2769; Abcam, Cambridge, MA), rabbit polyclonal anti-AHRR (ab108518; Abcam), 
rabbit polyclonal anti-CYP1B1 (ab137562; Abcam), or rabbit monoclonal anti-actin 
(Sigma-Aldrich, St. Louis, MO). Membranes were washed three times with PBST and 
incubated with either anti-rabbit or anti-mouse IgG HRP-link secondary antibody (Cell 
Signaling Technologies, Danvers, MA). Bands were visualized on film using SuperSignal 
West Dura Extended Duration Substrate (ThermoFisher Scientific) and standard film 
processor at various exposure times. 
 
CD107a Degranulation Assay 
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To examine NK cell activity, as previously described126,210–212, hESC-derived NK 
cells were harvested, washed, and plated at 100,000 cells per well of a V-bottomed 96-well 
plate co-cultured with K562 at a 2:1 effector-to-target ratio. NK cell only and NK+K562 
wells were incubated with anti-CD107a-AF700 (BD Biosciences, San Jose, CA) for 1 hour. 
Following incubation, 1:1500 Golgi Stop and 1:1000 Golgi Plug mix (BD Biosciences) 
was added and cells were incubated for 4 hours. Cells were washed with PBS and 
counterstained with Near-IR Live/Dead Fixable Dye (ThermoFisher Scientific). Cells were 
washed again and co-stained with the following antibodies (all anti-human): CD3-PE-
Texas Red (eBioscience, San Diego, CA), CD14 PE-Texas Red (eBioscience), CD19-PE-
Texas Red (eBioscience), and CD56-PE (Beckman Coulter, Indianapolis, IN) for 30 
minutes at 4°C. Cells were then transferred to FACS tubes and analyzed. 
 
Fluorescent Activated Cell Sorting (FACS) of NKP, cNK, and ILC3 derived from 
hESCs 
To assess the effects of AHR modification on NK cell and ILC specification, non-
adherent hematopoietic cells derived from hESCs on Day 11+28 cultured in NKDM 
supplemented with DMSO, SR-1, or TCDD were harvested as single-cell suspensions. 
Cells were washed with DPBS, filtered, and stained with the following antibodies (all anti-
human): CD56-BV421,  CD94-PerCP-Cy5.5, CD117-PECy7, and LFA-1 (CD11a/CD18)-
APC-R700 in sterile FACS Buffer (DPBS + 2% FBS and 0.1% sodium azide) for 30 
minutes at 4°C. Cells were washed with FACS buffer and cells were counterstained with 
Sytox Blue (ThermoFisher Scientific) immediately prior to sorting. Live NKP, cNK, and 
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ILC3 populations were sorted directly into FACS tubes containing NKDM basal media 
using a FACSAria II (BD Biosciences) cell sorter. Cells were immediately centrifuged, 
washed once with PBS, and processed from total RNA isolation as described above. 
 
Statistical Analyses 
Differences between groups were compared either with student’s t-test or one-
way/two-way ANOVA using Prism 6 (GraphPad Software, San Diego, CA). Results were 
considered statistically significant at p-values < 0.05. 
 
RESULTS 
Small molecule antagonism of AHR enhances early hemato-endothelial 
differentiation from hESCs 
To establish whether AHR mediates development of the earliest human 
hematopoietic cells, we differentiated hESCs using a two-stage defined culture system, as 
previously described (Figure 3-1A)77,213. We first assessed whether endogenous AHR was 
expressed in undifferentiated hESCs and hESCs differentiating into hemato-endothelial 
cells using qRT-PCR. AHR expression was increased 4.30±1.24 fold in the differentiated 
cell population at Day 6+3 relative to undifferentiated hESCs and became significantly 
increased at Day 6+5 (7.33±1.24 fold, p<0.01) (Supplemental Figure 3-1A). We also 
observed a corresponding increase in the expression of two downstream effector targets of 
AHR signaling (CYP1A1 and CYP1B1). These data indicate that endogenous AHR activity 
is upregulated at the onset of hemato-endothelial differentiation from hESCs, suggesting 
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that AHR is implicated in early hematopoiesis. We next treated hESCs with SR-1 or TCDD 
to modulate AHR signaling, or DMSO vehicle control. Following 4 days of culture, hESCs 
treated with 1 µM SR-1 had reduced expression of CYP1A1 and CYP1B1, whereas hESCs 
treated with TCDD yielded a significantly increased expression of CYP1A1 and CYP1B1 
as compared to DMSO normalized controls. We also confirmed that there were no 
significant cytotoxic effects on hESCs due to the presence of SR-1 or TCDD (Supplemental 
Figure 3-1C). Together, SR-1 and TCDD can effectively be used as agents to selectively 
regulate AHR-mediated activity in hESCs. 
We next investigated differentiating hemato-endothelial cells when exposed to SR-
1 or TCDD. As early as Day 6+3, there was a marked increase in the total percentage of 
CD34+CD144+ (1.71±0.22 fold, p<0.05) and CD34+CD31+ (1.58±0.28 fold) cells that have 
dual hemato-endothelial cell developmental potential in SR-1 treated hESCs as compared 
to DMSO controls214–216 (Figure 3-1B & 3-1C). As differentiation continued to Day 6+6, 
there were also notable increases in the total percentage of both CD34+CD31+ (1.62±0.12 
fold, p<0.05) hemato-endothelial cells and budding CD34+CD43+ (1.36±0.12 fold) 
hematopoietic progenitor cells70,77,199,204 when SR-1 treatment was applied. At Day 6+9, 
there was a significant increase in development of CD34+CD45+ hematopoietic progenitor 
cells77,93,217 (1.40±0.11, p<0.05) in the SR-1 treated cells. We also observed development 
of more terminally differentiated hematopoietic phenotypes (CD34-CD43+ and CD34-
CD45+) when hESCs were treated with TCDD. This effect was most pronounced at the 
Day 6+9 time point, where there was a reduction in the total percent of CD34+CD144+ 
(0.33±0.13), CD34+CD31+ (0.49±0.06, p<0.05), CD34+CD43+(0.67±0.09, p<0.05), and 
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CD34+CD45+ (0.44±0.06, p<0.05) progenitor cells with an increase in the total percent of 
CD34- hematopoietic cells. Taken together, these data demonstrate that AHR inhibition 
with SR-1 promotes early hemato-endothelial cell development, whereas AHR 
hyperactivation with TCDD accelerates differentiation towards more terminally 
differentiated hematopoietic lineages.   
 
Increased AHR-mediated production of hESC-derived hemato-endothelial cells is not 
due to increased proliferation of CD34+ cells 
Since we observed that SR-1 treatment increased the total percentage of CD34+ 
cells derived from hESCs, we next questioned whether this was caused by increased 
proliferation and/or cycling of developed CD34+ cells. We sorted Day 6+5 CD34+CD45+ 
hematopoietic progenitor cells and expanded them over the course of 15 days in expansion 
media supplemented with SR-1, TCDD, or DMSO. In parallel, we sorted CD34+CD45+ 
human UCB as a positive control. The absolute number of nucleated cells derived from 
UCB and treated with either DMSO, SR-1, and TCDD expanded at a significantly greater 
rate than their counterparts derived from Day 6+5 hESCs beginning by Day 9 of culture 
(Supplemental Figure 3-2A). By Day 15, there was a significant increase in the absolute 
number of nucleated cells in the UCB SR-1 group (14.2±1.0 x 106, p<0.05) relative to both 
DMSO (9.00±0.71 x 106) and TCDD (7.14±0.46 x 106) groups. However, we did not find 
a similar expansion of Day 6+5 hESC derived total cells as UCB-derived CD34+ cells 
between treatment groups at any time point. We further characterized the differentiating 
cells for development of CD34+CD45+ cells and calculated the total number of these cells 
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remaining over time. Again, by Day 15, there were significant increases in the number of 
CD34+CD45+ cells in the UCB SR-1 group (5.62±0.40 x 106, p<0.05) as compared to 
DMSO (1.69±0.13 x 106) and TCDD (0.15±0.01 x 106) treated UCB. As expected from the 
previous differentiation studies directly from spin-EBs, TCDD treatment of both UCB and 
hESC-derived CD34+CD45+ accelerated the differentiation to terminally differentiated 
CD34- hematopoietic cells as compared to DMSO, while SR-1 slowed this progression and 
retained hematopoietic cells in a progenitor state (Supplemental Figure 3-2B). These data 
suggest hESC-derived hemato-endothelial progenitor cells do not proliferate in response 
to SR-1 as do UCB CD34+ cells, but rather are enhanced through differentiation pathways. 
 
AHR-modulation in hESC-derived hemato-endothelial cells alters cell cycle 
progression 
We next evaluated whether increased hemato-endothelial phenotype was due to 
alterations in cell cycle progression when SR-1 was applied. We analyzed hESC-derived, 
non-adherent hematopoietic progenitor cells treated with either DMSO, SR-1, or TCDD at 
Day 6+5 to assess for the percentage of cells in G0/G1 (EdU-PIlow), S-phase (EdU+PI+), and 
G2/M (EdU-PIhi) (Supplemental Figure 3-3A). SR-1 treated hematopoietic progenitor cells 
had a significant increase for G0/G1 phase (43.7%±1.82, p<0.05) rather than S-phase 
(38.2%±1.00, p<0.01) as compared to DMSO treated controls (39.6%±0.35 and 
44.6%±0.48, respectively) (Supplemental Figure 3-3B). Conversely, TCDD treated 
hematopoietic progenitor cells were significantly enriched for S-phase (38.2%±1.03, 
p<0.001) rather than G0/G1 phase (25.8±0.34, p<0.01) as compared to the same controls. 
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Collectively, these data demonstrate AHR regulates hemato-endothelial and hematopoietic 
progenitor cell phenotype via cell cycle modification. 
 
AHR inhibition leads to functional hematopoietic progenitor cells and increased 
expression of key hematopoietic genes 
We next examined whether SR-1 supported the production of functional 
hematopoietic progenitor cells by standard methylcellulose-based colony forming unit 
(CFU) assays. SR-1 conditioning led to a marked increase in hematopoietic progenitor cell 
development compared to DMSO-treated controls (245.67±64.4 colonies vs. 60.3±1.20 
colonies, respectively, p<0.05), while the TCDD treated cells were significantly decreased 
(28.3±2.67 colonies, p<0.05) (Figure 3-2A). 
We further assessed key transcriptional regulators of human hematopoiesis that 
may be modulated by AHR expression within developing hemato-endothelial cells. We 
again analyzed the non-adherent hematopoietic fractions of differentiating hESC-derived 
cells treated with DMSO, SR-1, and TCDD and performed qRT-PCR probing for AHR-
related genes (AHR, CYP1B1), megakaryotic-erythropoietic genes218 (GATA1 and 
GATA2), a myelopoiesis regulator (PU.1)218, and a definitive hematopoiesis specific gene 
(CMYB)40,205,219. We found SR-1 treatment increased the expression of GATA1 (2.58±0.40 
fold) and GATA2 (6.85±0.74 fold, p<0.05) as early as Day 6+3 (Figure 3-2B). The mean 
GATA2:GATA1 at Day 6+3 was 2.67, and this positive ratio is in accord with the elevated 
GATA2 endogenous gene progression relative to GATA1 throughout early 
erythropoiesis220,221. TCDD treatment decreased the expression of GATA1 at Day 6+3 
  84 
(0.31±0.08 fold, p<0.05) as compared to DMSO controls and induced a reduction in 
GATA2 later at Day 6+6 (0.37±0.13 fold, p<0.05). There was a similar induction of PU.1 
with SR-1 treatment and reciprocal expression in TCDD treated hematopoietic cells at each 
time point. The increased fold-change of GATA1/GATA2 and PU.1 expression supports the 
enhanced production of CFU-E and CFU-M in SR-1 treated hematopoietic progenitor cells 
(Figure 3-2A). Moreover, SR-1 treatment also mediated a significant increase of CMYB at 
all time points. Collectively, these results further demonstrate AHR inhibition leads to 
enhanced activation of a functional and multilineage hematopoietic transcriptional 
program from hESCs. 
 
AHR knockout in hESCs promotes early hematopoietic differentiation 
We next investigated whether genetic deletion of AHR in hESCs would similarly 
mediate or even further enhance hemato-endothelial and hematopoietic progenitor cell 
production. To do this, we utilized CRIPSR/Cas9 to develop stable and clonally-derived 
hESCs cell lines with a deletion in AHR, preventing expression. Specifically, we utilized 
hESCs previously modified with a RUNX1c-tdTomato reporting cassette generated in our 
lab that demonstrates faithful measurement of early hemato-endothelial cells77. As 
previously described, these cells allowed us to observe EHT and isolate early human 
hematopoietic cells as they emerge from adherent endothelial cells. These cells now allow 
us to dually evaluate the effect of AHR gene modification on the induction of EHT77,205. 
We clonally expanded hESCs transfected with a gRNA target complementary to AHR exon 
1 and probed for modification using primers flanking the exon 1 sequence (Figure 3-3A). 
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We identified clones that yielded a 718bp amplicon (wild-type, WT), a 718bp amplicon 
with an additional 571bp amplicon indicative of partial exon 1 deletion (AHR+/-), and only 
the 571bp amplicon (AHR-/-) (Figure 3-3B). We confirmed functional loss of AHR protein 
with significant attenuation of the AHR-downstream targets aryl hydrocarbon receptor 
repressor (AHRR) and CYP1B1 in AHR-/--hESC-RUNX1c-tdTomato cells, as compared to 
K562 and NK92 positive controls, and wild-type hESC-RUNX1c-tdTomato cells (Figure 
3-3C). We additionally validated the on-target specificity of the gRNA by probing the AHR 
amplicons generated from the genomic DNA of each clone with Surveyor endonuclease as 
well as with direct sequencing (data not shown). These data confirmed we successfully 
generated heterozygous and homozygous deletions of AHR within hESCs. 
We next differentiated WT-, AHR+/--, and AHR-/--RUNX1c-tdTomato hESCs as in 
previous studies. At Day 6+3, there was approximately a 2-fold increase in development 
of hemato-endothelial cells (CD34+CD31+ and CD34+CD144+) as compared to WT- and 
AHR+/--hESCs at Day 6+3 (Figure 3-3D, quantified in Supplemental Figure 3-4A). We also 
found that AHR-/--RUNX1c-tdTomato hESCs produced more than a 2-fold increase in 
CD34+CD43+ and CD34+CD45+ hematopoietic progenitor cells at both Day 6+3 and Day 
6+6 time points. Importantly, the total percentage of CD34+ was not compromised as 
hematopoietic progenitor cells further differentiated into mature hematopoietic cells 
(CD34-CD33+, CD34-CD41a+, CD34-CD43+, CD34-CD45+). By Day 6+9, a majority of 
the AHR-/--hESC-derived cells continued to differentiate into matured hematopoietic 
lineages at a greater rate than WT- and AHR+/--hESCs, as indicated by an increased total 
percentage of CD34-CD45+ cells.  
  86 
Using the RUNX1c-tdTomato reporter, we also demonstrated an increased 
commitment towards RUNX1c+ cell development in AHR-/--RUNX1c-tdTomato hESCs as 
compared to WT- and AHR+/--RUNX1c-tdTomato hESCs. Specifically, there was a 5-fold 
expansion in the total percentage of tdTomato+ hematopoietic progenitor cells at both Day 
6+3 and Day 6+6 in AHR-/--RUNX1c-tdTomato hESCs compared to WT- and AHR+/--
RUNX1c-tdTomato hESCs (Figure 3-3E, quantified in Supplemental Figure 3-4B). We 
also further confirmed increased development of functional hematopoietic progenitor cells 
derived from AHR-/--RUNX1c-tdTomato hESCs compared to the controls using 
hematopoietic colony-forming unit assays. There was a significant increase in the total 
number of colonies formed in the AHR-/--hESCs (188.67±11.29 colonies, p<0.05) as 
compared to AHR+/--hESCs (54.0±2.08 colonies) and WT-hESCs (50.33±4.91 colonies) 
(Figure 3-3F). Collectively, these data suggest that genetic deletion of AHR in hESCs can 
robustly support functional hemato-endothelial differentiation. 
 
AHR inhibition enhances cNK cell differentiation from hESCs while AHR 
hyperactivation supports ILC3 cell phenotype 
Recent studies also demonstrate an important role of AHR to mediate development 
and function of both innate and adaptive immune cells129,222. Since AHR attenuation 
supports the differentiation of CD34+CD45+ hematopoietic progenitor cells (Figures 3-1B, 
3-3D), we assessed whether NK cell differentiation could also be enhanced from hESCs 
using defined conditions and a small molecule approach. Here, we used our previously 
described system for NK cell development from hESCs as a model for 
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lymphopoiesis122,160,161 (Figure 3-4A). By Day 11, spin-EBs produced a high percentage of 
CD34+CD45+ hematopoietic progenitor cells (range: 38.5%-65.0% for n=3 separate 
studies) (Figure 3-4B). At Days 11+21 (11 days in hematopoietic differentiation 
conditions, then 21 days in NK cell differentiation conditions) and Day 11+28, SR-1 treated 
hESC-derived hematopoietic cells demonstrated increased development of NK cells 
compared to DMSO treated controls, while TCDD treated hESC-derived hematopoietic 
cells had fewer phenotypic NK cells (Figures 3-4B & 3-4C). In addition to surface antigen 
acquisition, we also assessed lymphoid-specific gene expression in the hematopoietic cells 
produced in each treatment group. As compared to the DMSO treated control group, SR-1 
treated hESC-derived hematopoietic cells expressed a significantly higher amount of ID2 
(2.49±0.003 fold, p<0.01), TBX21/TBET (3.44±0.55 fold, p<0.05), and EOMES (5.12±0.52 
fold, p<0.05), transcriptional factors that mediate increased NK cell lineage commitment 
(Figure 3-4D). While we also observed a significant increase in TBX21/TBET (1.56±0.07 
fold, p<0.05) and EOMES (1.84±0.11 fold, p<0.05) in the TCDD treated hESC-derived 
hematopoietic cells, the fold-induction was significantly lower than those of the SR-1 
treated group. We further assessed the functionality of differentiated NK cells by assessing 
CD107a degranulation when stimulated with K562 target cells. SR-1 treated hESC-derived 
hematopoietic cells were comparable to DMSO treated controls in CD107a expression 
(58.1±0.67% vs. 47.2±2.76%), while TCDD treated hESC-derived hematopoietic cells 
expressed less CD107a (36.8±2.1%) (Figure 3-4E & 3-4F). Collectively, these data support 
SR-1 treatment of differentiating hESCs enhances the production of functional NK cells. 
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We further defined the identity of developing lymphoid phenotypes regulated by 
AHR activity by evaluating natural killer progenitor cells (NKP), conventional NK cells 
(cNK), and developmentally related innate lymphoid group 3 cells (ILC3)100,106,118. At Day 
11+28, hESC-derived hematopoietic cells treated with DMSO control produced cNK 
(CD94+CD117-CD56+LFA1+) and ILC3 (CD94-CD117+CD56+LFA1-) cells, but with a 
majority of the differentiated cells restricted to the NKP (CD94+CD117+) gate (Figures 3-
5A & 3-5B). Treatment with SR-1 significantly shifted hESC-derived hematopoietic cells 
away from NKPs (16.13±0.58% vs. 32.0±2.98%, p<0.01) and toward cNK cells 
(37.0±2.92% vs. 16.5±1,77%, p<0.001) compared to DMSO, with a significant reduction 
in the CD94-CD117+ population (Figure 3-5D). Treatment with TCDD also significantly 
shifted hESC-derived hematopoietic cells away from an NKPs, but conversely led to 
reciprocal increase in CD94-CD117+ cells (28.5±4.42% vs. 13.1±1.34%, p<0.01). When 
CD94-CD117+ cells were subgated to distinguish the presence of ILC3s, a significantly 
larger percentage TCDD treated hESC-derived hematopoietic cells were absent for LFA1, 
as compared to DMSO treated controls (69.4±4.57% vs. 48.8±4.81%, p<0.05) (Figure 3-
5E). We have previously shown that LFA1 expression is a unique and distinguishing 
marker between ILC3 (LFA1-) and cNK (LFA1+)106. We next sorted populations of cNK, 
NKP, and ILC3 and performed qRT-PCR to assess for both NK and ILC3 specific gene 
expression (Supplemental Figure 3-5A). As expected, hESC-derived phenotypic ILC3 
cells had a classical ILC3 gene signature, specifically RORc, IL1-R1, and IL-22. 
Additionally, ILC3 sorted populations were virtually deficient for GATA3, a critical 
transcriptional regulator of Group 2 ILCs223, and were decreased for TBX21/TBET 
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expression (Supplemental Figure 3-5B). These data further support that AHR inhibition 
promotes the differentiation of NK progenitor cells into mature cNK cells. Furthermore, 
for the first time, we demonstrate AHR hyperactivation promotes development of an ILC3 
phenotype from hESCs. 
 
DISCUSSION 
Human pluripotent stem cells provide an important starting point to better define 
key molecular and genetic drivers of human hemato-endothelial development. Here, we 
established that AHR antagonism using the chemical inhibitor SR-1, as well as AHR gene 
deletion using the CRIPSR/Cas9 system, enhances human EHT and hematopoietic 
progenitor cell development. In corresponding fashion, AHR hyperactivation using TCDD 
suppresses development of hematopoietic progenitor cells with multilineage potential and 
accelerates their differentiation into more matured hematopoietic lineages (Figure 3-6).  
To our knowledge, no other study has reported on the ability of AHR inhibition to 
promote early human hemato-endothelial differentiation. Gori et al. assessed the effect of 
AHR inhibition using short-term SR-1 treatment in a non-human primate iPSC model of 
hematopoiesis224. While these studies showed an increase in phenotypic CD34+CD45+ 
cells, there were no differences in the kinetics or quantity of CD34+ or CD34+CD31+ cells. 
SR-1 treated non-human primate iPSCs also did not enhance the total number of CFUs, 
unlike our findings using hESCs. These differences may be due to differences in culture 
conditions and/or possible species-specific differences. Indeed, AHR ligand selectivity, 
and AHR interaction with co-activator motifs all substantially differ between non-human 
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and primary human cells225–227. Our finding that AHR modulation can alter hematopoietic 
progenitor cell cycling are further corroborated by studies demonstrating AHR 
hyperactivation using FICZ in hiPSCs leads to increased EdU incorporation, which is 
similar to our result using TCDD130. Our model provides complementary data in which 
hESC-derived hematopoietic progenitor cells treated with SR-1 are reciprocally enriched 
in a G0/G1 state, presumably to support hematopoietic differentiation and progenitor cell 
maturation228–230. 
Interestingly, we also determined AHR gene deletion enhances development of 
early hematopoietic progenitor cells that are committing towards definitive hematopoietic 
lineages. We, and others, have reported the RUNX1c isoform is correlated with emerging 
definitive HSPCs from aorta-gonad-mesonephros region endothelial cells40,77. Using our 
previously developed RUNX1c-tdTomato reporter system to model EHT, we found hESCs 
harboring AHR gene deletion enhanced the differentiation of RUNX1c+ hematopoietic 
cells. We also observed an induction of a multilineage transcriptional program, including 
typical genes expressed during definitive hematopoiesis. One hypothesis for this effect is 
that AHR may function as a modulator of β-catenin/Wnt signaling. Exogenous activation 
of Wnt through GSK-3 inhibition has been recently shown to support a definitive 
hematopoietic phenotype from human pluripotent stem cells79. Interestingly, AHR and Wnt 
signaling have known associations both in normal embryological and disease pathogenesis. 
β-catenin gene expression (CTNNB1) is known to be overexpressed in Ahr-/- mice, causing 
the development of intestinal tumors134,231. Another study also demonstrated Ahr-/- mice 
had increased expression of genes regulated by β-catenin/Wnt signaling, specifically 
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within hematopoietic stem cells232. These Ahr-/- mice demonstrated splenomegaly, anemia, 
leukocytosis, and HSC accumulation outside the bone marrow. Together, these studies all 
implicate AHR as a potent regulator of definitive hematopoiesis. 
In addition to increased development of hemato-endothelial cells, we also found 
differentiation of lymphoid cells (NK cells) was increased by treatment of hESCs with SR-
1. These findings are complementary to prior studies that observed SR-1 treatment not only 
enhanced several transcription factors that are indispensable for NK cell differentiation, 
such as ID2, GATA3, and EOMES, but also promoted an increased absolute number of NK 
cells derived from mobilized peripheral blood CD34+ hematopoietic progenitor cells233. 
Our hESC-derived NK cells in the presence of SR-1 were functional, in that they 
comparably degranulated (CD107a) relative to controls when stimulated with K562 
targets. We further emphasize the role of AHR in hemato-lymphoid development by 
demonstrating AHR antagonism accelerates differentiation of NK progenitor cells into 
cNK phenotypes. This study illustrates that SR-1 can be added into currently defined 
differentiation protocols to enhance the efficiency and homogeneity of hESC-derived NK 
cells suitable to human clinical trials. 
 
Finally, to our knowledge, this is the first report demonstrating that ILC3s can be derived 
from human pluripotent stem cells. hESC-derived ILC3, like those located in secondary 
lymphoid tissue and peripheral blood, require AHR to drive their development106,119,234. 
Several studies have highlighted the critical immunomodulatory role ILC3 play in the gut 
mucosa, specifically in the production of IL-22 that is required for intestinal 
  92 
homeostasis235. It remains unclear whether they can be harnessed for clinical application, 
such as the attenuation of acute graft-vs-host disease post-hematopoietic stem cell 
transplantation236. hESCs, particularly in conjunction with a CRISPR/Cas9 gene editing 
system as we present, can be used as a powerful platform to better understand the 
development of a range of human ILCs, as well as to better analyze their effector 
phenotypes and therapeutic potential. 
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Figure 3-1. Small molecule antagonism of AHR enhances early hemato-endothelial 
development from hESCs. A) Schema of hESC differentiation into early hemato-
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endothelial cells as spin-embryoid bodies (spin-EBs). hESCs are made into spin-EBs at 
Day 0 and conditioned into mesoderm lineages for 6 days using defined cytokines (Stage 
1). At Day 6, spin-EBs are transferred into hemato-endothelial culture media (Stage 2) to 
promote endothelial and hematopoietic cell differentiation. For these studies, cells are 
treated with either 1 µM SR-1, 10nM TCDD, or DMSO vehicle control beginning at Day 
6+0 with media exchanges and/or harvesting performed at Day 6+3, Day 6+6, and Day 
6+9. B) Representative flow cytometry plots of one hESCs differentiation. Both adherent 
and non-adherent cell fractions are harvested at Day 6+3, Day 6+6, and Day 6+9 and 
assessed for endothelial cell (CD34+CD31+, CD34+CD144+) and hematopoietic 
progenitor cell (CD34+CD43+, CD34+CD45+) phenotype. C) Fold change of the total 
percentage of each hemato-endothelial phenotype for SR-1 and TCDD treated hESCs 
normalized to matched DMSO treated controls. n=4-6, error bars represent SEM, 
*p<0.05 as compared to DMSO treated controls by student’s t-test. N/A: Not applicable 
due to absence appreciable of CD34+CD45+ populations at Day 6+3 time point. 
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Figure 3-2. SR-1 treated hESCs demonstrate increased multilineage hematopoietic 
development. A) Non-adherent hematopoietic progenitor cells derived from hESCs 
differentiated in the presence of SR-1, TCDD, or DMSO controls were harvested at Day 
6+5 and seeded at 50,000 cells/dish in a standard methylcellulose colony-forming unit 
assay (CFU). Colonies were counted for each treatment group following 2 weeks of culture 
and scored for the following morphological subsets: BFU-E: burst-forming unit-erythroid; 
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CFU-E: colony-forming unit-erythroid; CFU-GM: colony-forming unit-granulocyte, 
macrophage, CFU-M: colony-forming unit-macrophage; CFU-GEMM: colony-forming 
unit-granulocyte, erythroid, macrophage, megakaryocyte. n=3, error bars represent SEM 
of the total number of colonies/50,000 cells seeded, *p<0.05 as assessed with one-way 
ANOVA + Tukey-Kramer multiple comparisons post-hoc test. B) Non-adherent 
hematopoietic progenitor cells derived from hESCs differentiated in the presence of SR-1, 
TCDD, or DMSO controls were harvested at Day 6+3, Day 6+6, and Day 6+9 time points 
and probed for gene expression by quantitative real-time PCR (qRT-PCR). For each gene, 
Ct values were normalized to GAPDH at each time point and data is presented as relative 
fold-change to DMSO treated controls. n=3, error bars represent SEM, *p<0.05, **p<0.01 
using student’s t-test. 
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Figure 3-3. CRISPR/Cas9 engineered hESCs with AHR deletion demonstrate 
increased early hemato-endothelial cell development. A) gRNA cassette design 
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targeting AHR. IS: insertion sequence; U6: Promoter, gRNA Exon 1: 22-nt gRNA specific 
to AHR exon 1, Term: termination sequence. B) Gel electrophoresis of PCR products 
produced from clonally-derived hESC-RUNx1c-tdTomato cells nucleofected with AHR 
gRNA cassette. Genomic DNA was harvested and primers flanking the AHR exon 1 locus 
were used to generate a PCR product with predicted full-length of 718 bp. WT: Negatively 
selected nucleofected hESC-RUNX1c-tdTomato hESCs; +/-: Individual clones with AHR 
heterozygous deletion (AHR+/-); -/-: Individual clones with AHR homozygous deletion 
(AHR-/-); *: 718bp amplicon, ^: 571bp amplicon. C) Immunoblot of protein lysate 
harvested from K562 cells (positive control), NK92 natural killer cells (positive control), 
wild-type hESC-RUNX1c-tdTomato (hESC-R1c-tdTom), heterozygous AHR deleted 
hESC-RUNX1c-tdTomato (+/-), and homozygous AHR deleted hESC-RUNX1c-tdTomato 
(-/-). AHRR: aryl hydrocarbon receptor repressor. D) Representative flow cytometry plots 
at Day 6+3, Day 6+6, and Day 6+9 from one differentiation of wild-type hESC-RUNX1c-
tdTomato (WT), heterozygous AHR hESC-RUNX1c-tdTomato deletion (AHR+/-), and 
homozygous AHR hESC-RUNX1c-tdTomato deletion (AHR-/-). Both adherent and non-
adherent cell fractions are harvested at Day 6+3, Day 6+6, and Day 6+9 and assessed for 
endothelial (CD31, CD144), and hematopoietic (CD33, CD41a, CD43, CD45) phenotype. 
E) Representative flow cytometry plots at Day 6+3 and Day 6+6 from one differentiation 
assessing for RUNX1c expression based on tdTomato fluorescent reporter protein. F) Non-
adherent hematopoietic progenitor cells derived from WT hESC-RUNX1c-tdTomato, 
AHR+/- hESC-RUNX1c-tdTomato, or AHR-/- hESC-RUNX1c-tdTomato were harvested at 
Day 6+5 and seeded at 50,000 cells/dish in a standard methylcellulose colony-forming unit 
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assay (CFU). Colonies were counted for each treatment group following 2 weeks of culture 
and scored for the following morphological subsets, as previously described. n=3, error 
bars represent SEM of the total number of colonies/50,000 cells seeded, *p<0.05 as 
assessed with one-way ANOVA + Tukey-Kramer multiple comparisons post-hoc test. 
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Figure 3-4. hESCs differentiated in the presence of SR-1 promotes the development 
of functional natural killer (NK) cells. A) Schema of hESC differentiation into lymphoid 
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cells as spin-embryoid bodies (spin-EBs). hESCs are made into spin-EBs at Day 0 and 
cultured in Stage 1 conditions with defined cytokines to promote mesoderm development 
for 11 days. At Day 11, spin-EBs are transferred onto OP9-DL1 in the presence of NK cell 
differentiation media (NKDM) to promote lymphoid differentiation. Cells are treated 
beginning at Day 11+0 with either 1 µM SR-1, 10nM TCDD, or DMSO vehicle control 
with media exchanges and/or harvesting performed every week for up to 4 weeks. B) At 
Day 11, differentiated spin-EBs (photo) are phenotyped for CD34+CD45+ expression and 
transferred to OP9-DL1 stroma in NKDM. Non-adherent hematopoietic cells cultured 
either in the presence of DMSO, SR-1, or TCDD were assessed for developing NK cell 
immunophenotype based on CD56+CD45+ expression at Days 11+21, and 11+28; 
representative flow cytometry plots from one differentiation are shown. C) Quantification 
of fold-change in total percentage of CD56+CD45+ cells at both Day 11+21 and Day 11+28 
when treated with DMSO, SR-1, or TCDD. SR-1 and TCDD treatments for each 
differentiation are normalized to DMSO controls. n=3 independent differentiation 
experiments, error bars represent SEM, *p<0.05 as assessed with two-way ANOVA + 
Tukey-Kramer multiple comparisons post-hoc test. D) Non-adherent hematopoietic 
progenitor cells derived from hESCs differentiated in the presence of SR-1, TCDD, or 
DMSO controls were harvested at Day 11+28 and probed for gene expression by 
quantitative real-time PCR (qRT-PCR). For each gene, Ct values were normalized to 
GAPDH at each time point and data is presented as relative fold-change to DMSO treated 
controls. n=3, error bars represent SEM, *p<0.05, #p<0.01 using student’s t-test. E) Non-
adherent hematopoietic progenitor cells derived from hESCs differentiated in the presence 
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of SR-1, TCDD, or DMSO controls were harvested at Day 11+28 and assessed for CD107a 
expression following 4 hours of co-culture with K562 target cells at 2:1 effector:target 
ratio. SSC: side scatter. Representative flow cytometry plots are shown from one 
experiment. F) Quantification of percentage of CD107a+ cells when treated with DMSO, 
SR-1, or TCDD at Day 11+28, n=2-3 replicates. 
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Figure 3-5. hESCs differentiated in the presence of SR-1 skews development towards 
conventional NK cells (cNK) while TCDD supports of the development of an innate 
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lymphoid cell (ILC) phenotype. A) Gating scheme for identifying cNK (CD94-CD117+), 
NK progenitor cells (NKP, CD94+CD117- and CD94+CD117-LFA1+), and ILC (CD94-
CD117+LFA1-) phenotypes. B) Representative flow cytometry profile of non-adherent 
hematopoietic cells differentiated from hESCs in the presence of DMSO, SR-1, or TCDD 
at Day 11+28. C) cNK, NKP, and NKP/ILC subpopulations from Day 11+28 DMSO, SR-
1, and TCDD differentiated hESCs assessed for CD56 and LFA (CD11a/CD18) surface 
antigen expression. Representative flow cytometry plots are shown, n=3. D) Total 
percentage of cNK, NKP, and NKP/ILCs present in the non-adherent fraction of 
differentiating hESCs in the presence of DMSO, SR-1, or TCDD at Day 11+28. n=3, error 
bars represent SEM, *p<0.05, **p<0.01, ***p<0.001 as compared to DMSO treated 
controls and assessed by two-way ANOVA + Tukey-Kramer multiple comparisons post-
hoc test. E) CD94-CD117+ subpopulations were further quantified for expression of LFA+ 
(NKP) and LFA- (ILC) by flow cytometry. n=3, error bars represent SEM, *p<0.05, 
**p<0.01 as compared to DMSO treated controls and assessed by two-way ANOVA + 
Tukey-Kramer multiple comparisons post-hoc test. 
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Figure 3-6. Model of AHR activity in human developmental hematopoiesis. AHR 
inhibition mediated by SR-1 (blue arrow) enhances the differentiation of both endothelial 
cells (ECs) and CD34+ hematopoietic progenitor cells. AHR hyperactivation mediated by 
TCDD (orange arrow) reciprocally acts to attenuate both EC and CD34+ hematopoietic 
progenitor cells. Once CD34+ have been differentiated, AHR inhibition deters further 
differentiation into CD34- terminally matured hematopoietic cells, while AHR 
hyperactivation supports this process. Upon production of natural killer progenitor (NKP) 
cells, AHR inhibition promotes conventional NK cell differentiation (cNK), while AHR 
hyperactivation promotes Group 3 ILC (ILC3) differentiation. 
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Supplemental Figure 3-1. AHR is implicated in normal human hematopoiesis and can 
be targeted by small molecules in hESCs. A) Non-adherent hematopoietic progenitor 
cells derived from hESCs were harvested at Day 6+3, Day 6+5, Day 6+7, and Day 6+9 
time points and probed for gene expression by quantitative real-time PCR (qPCR). For 
each gene, Ct values were normalized to GAPDH at each time point and data is presented 
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as relative fold-change as compared to undifferentiated hESCs. Differentiation was 
confirmed by a significant reduction of OCT4, a marker of pluripotency. n=3, error bars 
represent SEM, *p<0.05, **p<0.01, ***p<0.001, **** p<0.0001 using student’s t-test. B) 
Undifferentiated hESCs were cultured in the presence of 1 µM SR-1, 10nM TCDD, or 
DMSO vehicle control for 96 hours and probed for gene expression by qPCR. For each 
gene, Ct values were normalized to GAPDH at each time point and data is presented as 
relative fold-change as compared to DMSO treated hESCs. n=3, error bars represent SEM, 
*p<0.05 assessed by two-way ANOVA + Tukey-Kramer multiple comparisons post-hoc 
test. C) Both adherent and non-adherent cell fractions treated with either DMSO, SR-1, or 
TCDD were harvested at Day 6+3, Day 6+6, and Day 6+9 and probed for viability with 
Sytox Blue Live/Dead Stain. Total percentage of viable cells for each group and time point 
are plotted. n=3. 
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Supplemental Figure 3-2. AHR antagonism in early human hematopoietic 
progenitors derived from hESCs does not cause cell expansion. A) Left: Human 
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umbilical cord blood (UCB) and non-adherent Day 6+5 hematopoietic cells derived from 
hESCs were sorted for CD34+CD45+ and further cultured in StemSpan SFEM II expansion 
media for 15 additional days either in the presence of DMSO, SR-1, or TCDD. Every 3 
days, both the total cell number (Top right) and the total CD34+CD45+ cell number (bottom 
right) as assessed by flow cytometry was determined for each group. n=3 independent 
experiments. B) Representative flow cytometry plots throughout the time course assessing 
for total percentage of CD34+CD45+ phenotypes. 
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Supplemental Figure 3-3. AHR regulates cell cycle progression during hematopoietic 
cell development from hESCs. A) Non-adherent hematopoietic progenitor cells derived 
from hESCs were cultured in the presence of DMSO, SR-1, and TCDD until Day 6+5. Cell 
cycle phase was assessed using flow cytometry to determine the total percentage of G0/G1 
(EdU-PIlo), S-phase (EdU+PI+), or G2/M (EdU-PIhi). Representative flow cytometry plots 
are shown. B) Quantification of cell cycle analysis, n=3, *p<0.05, **p<0.01, ***p<0.001 
as assessed by two-way ANOVA + Tukey-Kramer multiple comparisons post-hoc test. 
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Supplemental Figure 3-4. CRISPR/Cas9 engineered hESCs with AHR deletion 
demonstrate increased early hemato-endothelial cell development. A) Quantification 
from flow cytometry profiles at Day 6+3, Day 6+6, and Day 6+9 of CD34+CD144+ and 
CD34+CD31+ endothelial cells and CD34+CD43+ and CD34+CD45+ early hematopoietic 
progenitor cells differentiated from wild-type hESC-RUNX1c-tdTomato (WT) or AHR-/- 
hESC-RUNX1c-tdTomato (AHR-/-). Total percentage of each cell population was 
normalized to WT and plotted as fold-change relative to WT. n=3 representative 
differentiations, *p<0.05 using student’s t-test. B) Quantification from flow cytometry 
profiles at Day 6+3 and Day 6+6 of tdTom+CD43+ and tdTom+CD45+ cells derived from 
WT or AHR-/- hESCs. n=3 representative differentiations, *p<0.05 using student’s t-test.
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Supplemental Figure 3-5. AHR hyperactivation in hESC-derived hematopoietic cells 
increase Group 3 ILC development. A) Day 11+28 hESC-derived non-adherent 
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hematopoietic cells were treated with SR-1 to enrich for CD94+CD117- (cNK), TCDD to 
enrich for CD94-CD117+LFA1- (ILC), and DMSO to enrich for CD94+CD117+ (NKP). 
Each phenotype was FACS sorted and RNA was harvested to assess for gene expression. 
*: Sorted population. B) qRT-PCR analysis of genes associated with cNK and ILC3 
development. Data are represented as fold-change in gene expression relative to NKP 
sorted cells. n=2, means of duplicate experiments are shown. 
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Supplemental Table 3-1. Oligonucleotide primers used for qRT-PCR. 
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CHAPTER 4 
Conclusions and Future Directions 
  116 
          This thesis research has identified novel genetic and molecular mechanisms that 
influence hemato-endothelial specification from human pluripotent stem cells. In Chapter 
2, we established a cell identification scheme to distinguish human hemogenic endothelial 
cells from vascular endothelial cells that lacked hematopoietic potential. We employed 
cutting-edge technological tools to perform RNA-sequencing of single cells from hESC-
derived hemogenic endothelium, non-hemogenic endothelium, and the earliest definitive 
hematopoietic progenitor cells to reveal distinct transcriptional signatures between each 
population. We identified many known transcriptional regulators of hemogenic 
endothelium (such as GATA2, FLI1, and SOX17) that were enriched in hESC-derived 
hemogenic endothelium and established additional candidates that may be integral to the 
mechanism of EHT (i.e. ESAM, TIMP3, RHOJ, DLL4). We further demonstrated that 
hESC-derived vascular endothelial cells without hematopoietic potential are heterogeneous 
and that a small subset can further transform into mesenchymal phenotypes. These studies 
provide novel data for expanding upon the current processes underlying human EHT and 
vasculogenesis. 
In Chapter 3, we determined AHR is implicated in the earliest events of human 
hematopoietic development. First, we found AHR inhibition enhanced the number of 
functional hematopoietic progenitor cells derived from hESCs, while AHR hyperactivation 
accelerated hematopoietic maturation. AHR inhibition and gene deletion enhanced the 
expression of key EHT genes, suggesting that AHR, in part, may contribute to hemogenic 
endothelial cell fate. Interestingly, many individual hESC-derived hemogenic endothelial 
cells expressed AHR and AHR-related downstream effector targets as compared to vascular 
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endothelial cells without hemogenic potential (Appendix 1). This supports a potentially 
novel role of the AHR pathway at the level of EHT. We also discovered that AHR functions 
as a molecular switch in human hemato-lymphoid specification. Here, we found AHR 
antagonism supported conventional NK cell (cNK) differentiation while AHR 
hyperactivation robustly produced phenotypic ILC3s. Taken together, these data provide a 
framework for improved NK cell differentiation from hESCs and also a platform to better 
assess the developmental biology and functionality of human ILC subsets. 
Although here we demonstrate methods to improve EHT and lymphoid lineage 
commitment using a human system, the challenge of generating long-term, engraftable 
HSPCs from hESC/hiPSCs remains. Previous studies from our lab demonstrate that 
although we can select and purify hESC-derived RUNX1c+ hematopoietic cells, these cells 
fail to contain long-term culture initiating cells (LTC-ICs)77. These assays are considered 
by many in the field as an in vitro surrogate to in vivo transplantation237,238. Other groups 
who have overexpressed important human EHT genes (i.e. GATA2, SOX17, HOXA9) to 
generate a hemogenic endothelium phenotype have at best shown improved time to 
engraftment, but fail at secondary transplantation67,69. Recently, expression of medial 
HOXA genes was found to be critical in mediating human EHT, however, even with 
overexpression in hESC-derived HSPCs, still failed to confer long-term engraftment68,239. 
Therefore, intrinsic cell modification alone is probably insufficient to support 
hESC/hiPSC-derived HSPCs. Instead, complementary differentiation techniques that 
additionally aim to recapitulate the embryological hematopoietic niche will need to be 
employed in future studies. 
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While hematopoietic stem cell transplantation using hESC/hiPSC-derived HSPCs 
is not currently possible, transient therapies using hiPSC-derived terminal hematopoietic 
products are quickly approaching clinical feasibility. hiPSC-derived erythroid cells for 
blood transfusion is an attractive initial option, in theory, because erythroid cells are easily 
differentiated in the presence of erythropoietin and are immunologically inert due to lack 
of MHC molecules. However, ex vivo expansion of enough erythroid cells suitable for a 
single unit of blood is currently not possible. It is also economically inefficient to scale 
hiPSC/hESC culture for erythogenesis (in fact, since 1 unit of donated blood has on average 
~2 x1012 erythroid cells, it is conservatively estimated a single unit of hiPSC-derived 
erythroid cells would cost $8,330)240,241. Similar limitations exist for hiPSC-derived 
platelets (megakaryocytes)242,243. 
hESC/hiPSC-derived NK cells are most primed for clinical translation, as they can 
be cultured and expanded to large numbers suitable for treating a single patient126. Of 
particular interest is that undifferentiated hESC/hiPSC can be modified with chimeric 
antigen receptors (CARs) and can be “personalized” to target essentially any foreign or 
tumor-presenting antigen of interest122,244,245. NK cells with surface CAR presentation can 
then be directly differentiated from these gene-modified hiPSCs using previously 
developed xenogenic-free and chemically-defined methods. Our data that demonstrates 
AHR inhibition of differentiating hESCs using StemRegnin-1 (a small molecule previously 
used in clinical trials142) skews hemato-lymphoid development towards cNK could be used 
advantageously to optimize hESC/hiPSC-derived NK cell production. Furthermore, we 
demonstrate that gene editing can effectively be accomplished in undifferentiated hESCs 
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using the CRISPR/Cas9 endonuclease system. We found this method to be highly efficient 
for hESC gene modification with high specificity to the AHR endogenous gene locus and 
without off-target effects. Such an approach could similarly be employed to engineer 
clinical quality hiPSCs and/or hiPSC-CAR-NK cells using a patient’s autologous cells in 
a highly efficient manner (Figure 4-1). Together, these strategies can be used to make 
hiPSC-based personalized medicine an even closer reality.  
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Figure 4-1. Clinical strategy for wide-scale hiPSC-based gene and cell therapy.  A) 
Dermal fibroblasts and/or peripheral mononuclear blood cells are harvested from a patient 
with defined genetic disease. hiPSCs are engineered from autologous cells via 
reprogramming with defined factors. Pathological mutations can be corrected through zinc-
finger nucleases (ZFN), TAL effector nucleases (TALEN), or clustered regulatory 
interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) gene-editing 
technologies. Gene-corrected hiPSCs can then be differentiated into the desired cell and/or 
tissue products prior to autologous transplantation via direct injection or seeding on a 
biocompatible scaffold. B) Prior to autologous cell transplantation, gene-corrected hiPSC-
derived cell products must first pass several safety checkpoints, such as viral, toxicology, 
and tumorigenicity screens, lack of teratoma expansion, and lack immune response to the 
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transplanted cells. Cells would also be immunophenotyped and banked for future patient 
use based on human leukocyte antigen (HLA) expression at this time. Furthermore, 
logistical hurdles such as obtaining intellectual property rights for product 
commercialization and regulatory agency approval must be in place prior to clinical trial.  
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APPENDIX 
 
 
Appendix 1. Violin plots of AHR-related genes in single hESC-derived hemato-
endothelial cells. Log-transformed FPKM gene expression of hESC-derived HE, non-
HE, and HP, as described in Chapter 2. Here, AHR and AHR downstream effector targets 
(notably CYP1A1 and CYP1B1) are enriched in hESC-derived HE and HP as compared to 
non-HE. 
 
 
 
 
 
 
